I-D. CURRICULUM VITAE
7/1/21
CURRICULUM VITAE
WILLIAM FRANK REGINE, MD, FACR, FACRO
____________________________________________________________________________________
DATE & PLACE OF BIRTH: September 23, 1961; Brooklyn, NY
OFFICE ADDRESS: UNIVERSITY OF MARYLAND MEDICAL SYSTEM
Department of Radiation Oncology
22 S. Greene Street, Room GGK0101
Baltimore, MD 21201
Telephone: (410) 328-2326
E-mail: wregine@umm.edu
ACADEMIC DEGREES:
B.S. 1983 State University of New York at Albany, Albany, New York (Chemistry, Summa Cum Laude)
M.D. 1987 State University of New York Health and Science Center at Syracuse, Syracuse, New
York
PROFESSIONAL APPOINTMENTS:
1987 - 1988 Transitional Intern, St. Joseph's Hospital, Syracuse, New York
1988 - 1991 Resident, Department of Radiation Oncology, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania
1991 - 1992 Fellow, Gastrointestinal – Head and Neck Malignancies, Departments of Radiation Oncology, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania and University of FL, Gainesville, FL
1992 - 1994 Assistant Member, Department of Radiation Oncology, St. Jude Children’s Research Hospital, Memphis, Tennessee
1992 - 1994 Assistant Professor, Section of Radiation Oncology, University of Tennessee, Memphis, Tennessee
1994 Assistant Professor and Acting Clinical Chief, Section of Radiation Oncology, University of Tennessee, Memphis, Tennessee
1994 - 1997 Assistant Professor, Department of Radiation Medicine, University of Kentucky, Lexington, Kentucky
1997 - 2002 Associate Professor, with Tenure, Department of Radiation Medicine, University of Kentucky, Lexington, Kentucky
1997 - 2002 Associate Professor, Joint Appointment, Department of Surgery, Division of Neurosurgery, University of Kentucky, Lexington, Kentucky
1998 - 2000 Associate Director for Clinical Research, Markey Cancer Center, University of Kentucky, Lexington, Kentucky
1998 - 2002 Co-Director, University of Kentucky Gamma Knife Radiosurgery Program
2000 - 2002 Vice-Chairman, Department of Radiation Medicine, University of Kentucky, Lexington, Kentucky
2002 Co-Director, Department of Radiation Medicine Residency Program, University of Kentucky, Lexington, Kentucky
2002 Professor, with Tenure, Department of Radiation Medicine, University of Kentucky, Lexington, Kentucky
2002 Professor, Joint Appointment, Department of Surgery, Division of Neurosurgery, University of Kentucky, Lexington, Kentucky
2004 - 2012 Director, Department of Radiation Oncology Residency Program, University of Maryland, Baltimore, Maryland
2003 - present Professor and Chairman, Department of Radiation Oncology University of Maryland School of Medicine, Baltimore, Maryland
2010 - 2012 Professor and Interim Chairman, Department of Diagnostic Radiology and Nuclear Medicine University of Maryland School of Medicine, Baltimore, Maryland
2012 – present Professor, Joint Appointment, Department of Diagnostic Radiology and Nuclear Medicine University of Maryland School of Medicine, Baltimore, Maryland
2012 - 2016 Clinical Director, Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, Maryland
2012 - present Executive Director, Maryland Proton Treatment Center (MPTC), University of Maryland,
Baltimore, Maryland
HONORS:
1979 New York State Regent’s College Scholarship
1981 State University of New York at Albany’s Honor Society: Signum Laudis
1982 Phi Beta Kappa
1984 - 1986 Honors – Epidemiology, Pediatrics, Anesthesiology, Hematology-Oncology, Otolaryngology, Radiation Oncology, Surgery
1991 Chief Resident, Radiation Oncology, Thomas Jefferson University Hospital, Philadelphia, PA
199. 1 American Cancer Society Clinical Oncology Fellowship Award
American Society for Therapeutic Radiology and Oncology – European Society for Therapeutic Radiology and Oncology Exchange Program Travel Grant Award
2006 Elected President of the Simon Kramer Society
2007 National Departmental Rank of “Top 10” in NIH Funding (5th – 2005)
2007 - 2014 Selected for Listing among “Best Doctors in Baltimore”
2013 Radiation Therapy Oncology Group “Outstanding Publication Award for 2008/2009”
2010 - 2013 Selected among “Super Doctors” in Mid-Atlantic-Washington Post Magazine
2011 Selected among “Top 1% of Doctors” U.S. News & World Report
2013 Inducted into Port Richmond High School Hall of Fame
2013 Inducted as a “Fellow” in the American College of Radiology
2015 American Board of Radiology Lifetime Volunteer Service Award for Radiation Oncology
2015 Inducted as a “Fellow” in the American College of Radiation Oncology
2015 ASTRO Abstract/Presentation Selected Among “Best of ASTRO”
2016 University of Maryland, Department of Radiation Oncology, “Never Be Afraid to Try”, Teacher of the Year Award
2016 Entrepreneur of the Year Award, University of Maryland, Baltimore
2016, 2017, 2019, 2020 Recognized as a "Top Doctor" by Baltimore Magazine
2018 Ulman Cancer Fund for Young Adults “Hope Award”
2018 2 is 10 Foundation “Advancement in Medicine Award”
2018 President-Elect, University of Maryland Medical Center Medical Staff
2019 The Daily Record Health Care Heroes 2019 “Lifetime Achievement Award”
2002 – 2008; 2020 Peer selected “Best Doctors in America”
CERTIFICATION/LICENSURE:
Diplomat, National Board of Medical Examiners (1987)
Medical Physician and Surgeon (Pennsylvania)
Medical Physician and Surgeon (Tennessee)
Medical Physician and Surgeon (Kentucky)
Medical Physician and Surgeon (Maryland)
Medical Physician and Surgeon (California)
Board Certified in Radiation Oncology (1992)
Paul Scherrer Institute (PSI) Winter School for Proton Therapy (2014)
LAB RESEARCH EXPERIENCE:
1982 - 1983 Synthesized and studied steric hindrances within sulfonamide series. Supervised by William Closson, Ph.D., State University of New York at Albany
1991 Studied Murine bone marrow macrophage colony-forming unit response to radiation and hyperthermia. Supervised by Michael D. O'Hara, Ph.D., Department of Radiation Oncology, Thomas Jefferson University Hospital
PROFESSIONAL SOCIETY MEMBERSHIPS:
American College of Radiology
American College of Radiation Oncology
American Medical Association
American Radium Society
American Society of Therapeutic Radiologists and Oncologists
American Society of Clinical Oncology
Baltimore City Medical Society
Radiation Oncology Institute
Radiation Therapy Oncology Group (now NRG)
Phi Beta Kappa
Simon Kramer Society
The Rare Cancer Network
PUBLICATIONS:
ORIGINAL PEER-REVIEWED ARTICLES
1. Sagerman RH, Kotlove DJ, Regine WF, Chung CT, King GA, Dalal PS. Stage II Seminoma: Results of Postorchiectomy Irradiation. Radiology 172: 565-568, 1989.
2. Regine WF, Ayyangar K, Komarnicky LT, Bhandare N, Mansfield CM. Computer-CT Planning of the Electron Boost in Definitive Breast Irradiation. Int J Radiat Oncol Biol Phys 20(1): 121-125, 1991.
3. Regine WF, Kramer S. Pediatric Craniopharyngiomas: Long-Term Results of Combined Treatment with Surgery and Radiation. Int J Radiat Oncol Biol Phys 24(4): 611-617, 1992.
4. Regine WF, Mohiuddin M. Impact of Adjuvant Therapy on Locally Advanced Adenocarcinoma of the Stomach. Int J Radiat Oncol Biol Phys 24(5): 921-927, 1992.
5. Regine WF, Mohiuddin M, Kramer S. Long-Term Results of Pediatric and Adult Craniopharyngiomas Treated with Combined Surgery and Radiation. Radiotherapy Oncol 27: 13-21, 1993.
6. Regine WF, Mendenhall WM, Parsons JT, Stringer SP, Cassisi NJ, Million RR. Radiotherapy for Adenoid Cystic Carcinoma of the Palate. Head & Neck 15: 241-244, 1993.
7. Regine WF, Fontanesi J, Kumar P, Ayers D, Bowman LC, Pappo AS, Coffey DH, Avery L, Rao BN, Kun LE. Local Tumor Control in Rhabdomyosarcoma Following Low-Dose Irradiation:comparison of Group II and select Group III patients. Int J Radiat Oncol Biol Phys 31(3): 485-491, 1995.
8. Kumar P, Mulhern RK, Regine WF, Rivera GK, Kun LE. A Prospective Neurocognitive Evaluation of Children Treated with Additional Chemotherapy and Craniospinal Irradiation Following Isolated Central Nervous System Relapse in Acute Lymphoblastic Leukemia. Int J Radiat Oncol Biol Phys 31(3): 561-566, 1995.
9. Regine WF, Fontanesi J, Kumar P, Zeitzer K, Greenwald C, Bowman L, Shapiro DN, Rao BN, Kun LE. A Phase II Trial Evaluating Selective Use of Altered Radiation Dose and Fractionation in Patients with Unresectable Rhabdomyosarcoma. Int J Radiat Oncol Biol Phys 31(4): 799-805, 1995.
10. O'Hara MD, Pollard M, Wheatley G, Regine WF, Mohiuddin M, Leeper D. Thermal Response and Hyperthermic Radiosensitization of SCID Mouse Bone Marrow CFU-C. Int J Radiat Oncol Biol Phys 31(4): 905-910, 1995.
11. Mohiuddin M, Regine WF, Stevens J, Rosato F, Barbot D, Biermann W, Cantor R. Combined Intraoperative Radiation and Perioperative Chemotherapy for Unresectable Cancers of the Pancreas. J Clin Oncol 13: 2764-2768,1995.
12. Mohiuddin M, Regine WF, Marks G. Prognostic Significance of Tumor Fixation in Rectal Cancer: Implications for Adjunctive Radiation Therapy. Cancer 78(4): 717-722, 1996.
13. Robbins KT, Kumar P, Regine WF, Wong FSH, Weir III AB, Flick P, Kun LE, Palmer R, Murray T, Fontanesi J, Ferguson R, Thomas R, Hartsell W, Paig CU, Salazar G, Norfleet L, Hanchett CB, Harrington V, Niell B. Efficacy of Targeted Supradose Cisplatin and Concomitant Radiation Therapy for Advanced Head and Neck Cancer: The Memphis Experience. Int J Radiat Oncol Biol Phys 38(2): 263-271, 1997.
14. Regine WF, Valentino J, Sloan DA, Patel P, Mohiuddin M, Kenady DE. Efficacy of Postoperative Radiation Therapy for Recurrent Squamous Cell Carcinoma of the Head and Neck. Int J Radiat Oncol Biol Phys 39(2): 297-302, 1997.
15. Young B, Regine WF, Sanders MF, Strottmann JM . Whole Brain Radiation Therapy for Treating Cerebral Metastasis May Not Be Necessary After Stereotactic Radiosurgery Performed with Magnetization-Prepared, Rapid-Acquisition Gradient Echo MRI with Triple-Dose Contrast. Radiosurgery 2: 72-77,1997.
16. Mohiuddin M, Regine WF, Marks GJ, Marks JW. High-Dose Preoperative Radiation and the Challege of Sphincter-Preserving Surgery for Cancer of the Distal 2 cm of the Rectum. Int J Radiat Oncol Biol Phys 40(3): 569-574, 1998.
17. Regine WF, Hodes JE, Patchell RY. Intracranial Germinoma: Treatment with Radiosurgery Alone. J Neuro-Onc 37(1): 75-77, 1998.
18. Klyachkin ML, Schwartz RW, Cibull M, Munn RK, Regine WF, Kenady DE, McGrath PC, Sloan DA. Thyroid Lymphoma: Is There a Role for Surgery? The American Surgeon 64: 234-238,1998.
19. Rudoltz MS, Regine WF, Langston JW, Sanford RA, Kovnar EH , Kun LE. Multiple Causes of Cerebrovascular Events in Children with Tumors of the Parasellar Region. J Neuro-Onc 37(3): 251-261, 1998.
20. Meigooni AS, Valentino J, Regine WF. An Innovative Method for Optimization of Intraluminal Brachytherapy Dose Delivery for Tumors Involving the Carina. Journal of Brachytherapy International 14: 185-189, 1998.
21. Mohiuddin M, Young BA, Regine WF. The Effects of Gamma Knife Radiosurgery on Tinnitus in Patients with Acoustic Neuromas. Journal of Radiosurgery 1(4): 265-270, 1998.
22. Patchell RA, Tibbs PA, Regine WF, Dempsey RJ, Mohiuddin M, Kryscio RJ, Markesbery WR, Foon KA, Young B. Postoperative Radiotherapy in the Treatment of Single Metastases to the Brain: A Randomized Trial. JAMA 280(17): 1485-1489, 1998.
23. Fujita M, Rudoltz MS, Canaday DJ, Patel P, Machtay M, Pittard MQ, Mohiuddin M, Regine WF. Second Malignant Neoplasia in Patients with T1 Glottic Cancer Treated with Radiation. Laryngoscope 108: 1853-1854, 1998.
24. Canaday DJ, Regine WF, Mohiuddin M, Zollinger W, Machtay M, Lee J, Schultz D, Rudoltz MS. Significance of Pretreatment Hemoglobin Level in Patients with T1 Glottic Cancer. Radiation Oncology Investigations 7: 42-48, 1999.
25. Regine WF, Valentino J, Sloan DA , Patel P, Pittard MQ, Kenady DE, Mohiuddin M. Postoperative Radiation Therapy for Primary vs. Recurrent Squamous Cell Carcinoma of the Head and Neck: Results of a Comparative Analysis. Head & Neck 21: 554-559, 1999.
26. Mohiuddin M, Fujita M, Regine WF, Meigooni AS, Ibbott GS, Ahmed M. High Dose Spatially Fractionated Radiation (GRID): A New Paradigm in the Management of Advanced Cancers. Int J Radiat Oncol Biol Phys 45(3): 721-727, 1999.
27. Sloan DA, Witzke DB, Plymale MA, Sloan PA, Regine WF, Valentino J, Schwartz RW, Kenady DE. A Multidisciplinary Workshop to Teach Head and Neck Oncology to Residents: Results of a Pilot Study. Journal of Cancer Education 14(4): 228-232, 1999.
28. Valentino J, Weinstein L, Rosenblum R, Regine WF, Weinstein M. Radiation and Intra-Arterial Cisplatin. Effects on Arteries and Free Tissue Transfer. Arch Otolaryngol Head Neck Surg 126: 215- 219, 2000.
29. Mohiuddin M, Regine WF, John WJ, Hagihara PF, McGrath PC, Kenady DE, Marks G. Preoperative Chemoradiation in Fixed Distal Rectal Cancer: Dose Time Factors for Pathological Complete Response. Int J Radiat Oncol Biol Phys 46(4): 883-888, 2000.
30. Regine WF, John WJ, McGrath P, Strodel WE, Mohiuddin M. The Feasibility of Dose Escalation Using Concurrent Radiation and 5-Fluorouracil Therapy Following Pancreaticoduodenectomy for Pancreatic Carcinoma. J of Hepatobiliary Pancreat Surg 7: 53-57, 2000.
31. Regine WF, Patchell RA, Strottman J, Sanders M, Meigooni AS, Young AB. Preliminary Report of a Phase I Study of Combined Fractionated Stereotactic Radiosurgery and Conventional External Beam Radiation Therapy for Unfavorable Gliomas. Int J Radiat Oncol Biol Phys 48(2): 421-426, 2000.
32. Regine WF, Valentino J, John J, Storey G, Sloan D, Kenady D, Patel P, Pulmano C, Arnold S, Mohiuddin M. High-Dose Intra-Arterial Cisplatin and Concurrent Hyperfractionated Radiation Therapy in Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck: Report of a Phase II Study. Head & Neck 22: 543-549, 2000.
33. Mohiuddin M, Hayne M, Regine WF, Hanna N, Hagihara P, McGrath P, Marks GM. Prognostic Significance of Postchemoradiation Stage Following Preoperative Chemotherapy and Radiation for Advanced/Recurrent Rectal Cancers. Int J Radiat Oncol Biol Phys 48(4): 1075-1080, 2000.
34. Gamburg ES, Regine WF, Patchell RA, Strottmann JM, Mohiuddin M, Young AB. The Prognostic Significance of Midline Shift on Survival of Patients Presenting with Glioblastoma Multiforme. Int J Radiat Oncol Biol Phys 48(5): 1359-1362, 2000.
35. Nicol B, Regine WF, Courtney C, Meigooni AS, Sanders M, Young B. Gamma Knife Radiosurgery Using 90 Gy for Trigeminal Neuralgia. J Neurosurg 93(S3): 152-154, 2000.
36. Regine WF, Patchell RA, Strottman J, Meigooni AS, Sanders M, Young BA. Combined Stereotactic Split-Course Fractionated Gamma Knife Radiosurgery and Conventional Radiation Therapy for Unfavorable Gliomas: A Phase I Study. J Neurosurg 93(S3): 37-41, 2000.
37. Regine WF, Valentino J, Arnold SM, Haydon RC, Sloan D, Kenady D, Strottman J, Pulmano C, Mohiuddin M. High-Dose Intra-Arterial Cisplatin Boost with Hyperfractionated Radiation Therapy for Advanced Squamous Cell Carcinoma of the Head and Neck. JCO 19(14): 3333-3339, 2001.
38. Sanghavi SN, Miranpuri SS, Chappell R, Buatti JM, Sneed PK, Suh JH, Regine WF, Weltman E, King VJ, Goetsch SJ, Breneman JC, Sperduto PW, Scott C, Mabanta S, Mehta MP. Radiosurgery for Patients with Brain Metastases: A Multi-Institutional Analysis, Stratified by the RTOG Recursive Partitioning Analysis Methodology. Int J Radiat Oncol Biol Phys 51(2): 426-434, 2001.
39. Regine WF, Scott C, Murray K, Curran W. Neurocognitive Outcome in Brain Metastasis Patients Treated with Accelerated Fractionation vs. Accelerated Hyperfractionated Radiotherapy: An Analysis From Radiation Therapy Oncology Group Study 91-04. Int J Radiat Oncol Biol Phys 51(3): 711-717, 2001.
40. Jackson TR, Regine WF, Wilson D, Davis DG. Cerebellar Liponeurocytoma: Case Report, Review of the Literature and Therapeutic Implications. J Neurosurg 95(S4): 700-703, 2001.
41. Regine WF, Huhn JL, Patchell RA, St. Clair WH, Strottmann J, Meigooni AS, Sanders M, Young AB. Risk of Symptomatic Brain Tumor Recurrence and Neurologic Deficit After Radiosurgery Alone in Patients With Newly Diagnosed Brain Metastases: Results and Implications. Int J Radiat Oncol Biol Phys 52(2): 333-338, 2002.
42. Meigooni AS, Parker SA, Zheng J, Kalbaugh KJ, Regine WF, Mohiuddin M. Dosimetric Characteristics with Spatial Fractionation Using Electron GRID Therapy Med Dosimetry 27(1): 37-42 2002.
43. Regine WF, Reid B, Patchell RA, St.Clair WH, Meigooni AS, Sims J, Sanders M, Young AB. Efficacy of 20 Gy Stereotactic Radiosurgery for < 2 cm Brain Metastases. Radiosurgery 4: 134-142, 2002.
44. Regine WF, Valentino J, Arnold SM, Sloan D, Kenady D, Strottmann J, Mohiuddin M. A Phase II Study of Concomitant Hyperfracionated Radiation Therapy and Double Dose Intra-Arterial Cisplatin for Squamous Cell Carcinoma of the Head and Neck. Technology in Cancer Research and Treatment 1: 133-140, 2002.
45. Sathishkumar S, Dey S, Meigooni AS, Regine WF, Kudrimoti M, Ahmed MM, Mohiuddin M. The Impact of TNF-α Induction on Therapeutic Efficacy Following High Dose Spatially Fractionated (GRID) Radiation. Technology in Cancer Research and Treatment 1: 141-147, 2002.
46. Mohiuddin M, Chendil D, Dey S, Alcock RA, Regine WF, Mohiuddin M, Ahmed MM. Influence of p53 Status on Radiation and 5-Flourouracil Synergy in Pancreatic Cancer Cells. Anticancer Research 22: 825-830, 2002.
47. Sneed PK, Suh JH, Goetsch SJ, Sanghavi SN, Chappell R, Buatti JM, Regine WF, Weltman E, King VJ, Breneman JC, Sperduto PW, Mehta MP. A Multi-Institutional Review of Radiosurgery Alone vs. Radiosurgery with Whole Brain Raditherapy as the Initial Management of Brain Metastases. Int J Radiat Oncol Biol Phys 53(3): 519-526, 2002.
48. Valentino J, Spring PM, Shane M, Arnold SM, Regine WF. Interval Pathologic Assessments In Patients Treated with Concurrent Hyperfractionated Radiation and Intraarterial Cisplatin (Hyperradplat). Head and Neck 24: 539-544, 2002.
49. Hahn SM, Bernard EJ, Regine WF, Mohiuddin M, Haller DG, Stevenson JP, Smith D, Pramanik, B, Tepper J, Delaney TF, Kiel KD, Morrison B, Deutsch P, Muschel RJ, McKenna WG. A Phase I Trial of the Farnesyltransferase Inhibitor L-778,123 and Radiotherapy for Locally Advanced Lung and Head and Neck Cancer. Clinical Cancer Research 8: 1065-1072, 2002.
50. Mohiuddin M, Kudrimoti M, Regine WF, McGrath P, Hanna N, Meeker T, John W. Concurrent Infusional Gemcitabine and Radiation in the Treament of Advanced Unresectable GI Malignancy: A Phase I Study. Cancer Journal 8: 255-262, 2002.
51. Mohiuddin M, Damodaran C, Swatee D, Alcock R, Regine WF, Mohiuddin M, Ahmed MM. Influence of p53 Status on Radiation and 5 - Flourouracil Synergy in Pancreatic Cancer Cells. Anticancer Research 22: 825-830, 2002.
52. Patchell RA, Regine WF, Ashton P, Tibbs PA, Wilson D, Shappley D, Young BY. A phase I Trial of Continuously Infused Intratumoral Bleomycin for the Treatment of Recurrent Glioblastoma Multiforme. J Neuro-Onc 60: 37-42, 2002.
53. Dey S, Spring PM, Arnold S, Valentino J, Chendil D, Regine WF, Mohiuddin M, Ahmed MM. Low-Dose Fractionated Radiation Potentiates the Effects of Paclitaxel in Wild-type and Mutant p53 Head and Neck Tumor Cell Lines. Clin Ca Res 9: 1557-1565, April 2003.
54. Anderson T, Regine WF, Kryscio R, Patchell RA. Neurologic complications of bladder cancer. A review of 359 cases. Cancer 97: 2267-72, 2003.
55. Patchell RA, Regine WF. The Rational for Adjuvant Whole Brain Radiation Therapy with Radiosurgery in the Treatment of Single Brain Metastases. Tech Ca Res Treat 2(2): 111-115, 2003.
56. Chin LS, Szerlip NJ, Regine WF. Stereotactic Radiosurgery for meningiomas. Neurosurg Focus 14(5): 1-6, 2003.
57. Flannery TW, Suntharalingam M, Kwow Y, Koffman BH, Amin PP, Chin LS, Nicol B, Fowler, Young AB, Regine WF. Gamma Knife stereotactic radiosurgery for synchronous versus metachronous solitary brain metastases from non-small cell lung cancer. Lung Cancer, 42: 327-333, 2003.
58. Arnold SM, Regine WF, Ahmed MM, Valentino J, Spring P, Kudrimoti M, Kenady D, Desimone P, Mohiuddin M. Low-dose Fractionated Radiation as a Chemopotentiator of Neoadjuvant Paclitaxel and Carboplatin for Locally Advanced Squamous Cell Carcinoma of the Head and Neck: Results of a New Treatment Paradigm. Int J Radiat Oncol Biol Phys 58(5): 1411-1417, 2004.
59. Shehata MK, Young AB, Reid B, Patchell RA, St Clair W, Sims J, Sanders M, Meigooni AS, Mohiuddin M, Regine WF. Stereotatic Radiosurgery (SRS) of 468 Brain Metastases ≤ 2 cm: Implications for SRS Dose and Whole Brain Radiation Therapy (WBRT). Int J Radiation Oncology Biol Phys 59(1): 87-93, 2004.
60. Regine WF, Schmitt FA, Scott CB, Dearth C, Patchell RA, Nichols, RC, Gore EM, Franklin RL, Suh JH, Mehta MP. Feasibility of Neurocognitive Outcome Evaluations in Patients with Brain Metastases in a Multi-Institutional Cooperative Group Setting: Results of Radiation Therapy Oncology Group Trial BR-0018. Int J Radiation Oncology Biol Phys 58(5): 1346-1352, 2004.
61. Cheuk AV, Chin LS, Petit JH, Herman JM, Fang HB, Regine WF. Imaging Correlates of Gamma Knife Outcome in Trigeminal Neuraliga. Int. J Radiation Oncology Biol. Phys 60(2): 537-541, 2004.
62. Regine WF, Rogozinska A, Kryscio RJ, Tibbs PA, Young AB, Patchell RA. Recursive Partitioning Analysis Classifications I And II: Applicability Evaluated In A Randomized Trial For Resected Single Brain Metastases. Am J Clin Onc 27(5): 505-509, 2004.
63. Martin NE, Brunner TB, Kiel KD, DeLaney TF, Regine WF, Mohiuddin M, Rosato EF, Haller DG, Stevenson JP, Smith D, Pramanik B, Tepper J, Tanaka WK, Morrison B, Deutsch P, Gupta AK, Muschel RJ, McKenna WG, Bernhard EJ, Hahn SM. A Phase I Trial of the Dual Farnesyltransferase and Geranylgeranyltransferase Inhibitor L-778,123 and Radiotherapy for Locally Advanced Pancreatic Cancer. Clinical Cancer Research, 10: 547- 554, 2004.
64. DiBiase SJ, Kwok Y, Yavino S, Arena C, Naqvi S, Temple R, Regine WF, Amin P, Guo C, Chin LS. Factors Predicting Local Tumor Control After Gamma Knife Stereotactic Radiosurgery for Benign Intracranial Meningiomas. Int J Radiation Oncology Biol Phys 60(5): 1515-1519, 2004.
65. Patchell R, Tibbs P, Regine WF, Payne R, Saris S, Kryscio R, Mohiuddin M, Young B. A randomized Trial of Direct Decompressive Surgical Resection in the Treatment of Spinal Cord Compression caused by metastatic cancer. The Lancet 366: 643-648, 2005.
66. Gaugler J, Hanna N, Linder J, Given CW, Tolbert V, Kataria R, Regine WF. Cancer Caregiving and Subjective Stress: A Multi-Site Multi-Dimensional Analysis. Psycho-Oncology 14: 771-785, 2005.
67. Spring P, Valentino J, Arnold S, Sloan D, Kenady D, Kudrimoti M, Haydon RC, Lee C, Mohiuddin M, Regine WF. Long-Term Results of Hyperfractionated Radiation and High-Dose Intraarterial Cisplatin for Unresectable Oropharyngeal Carcinoma: Cancer, 104(8): 1765-1771, 2005.
68. Ma L, Kwok Y, Regine WF. Concomitant GRID Boost for Gamma Knife Radiosurgery: Med Phys 32(11): 3419-3423, 2005.
69. Ma L, Kwok Y, Chin LS, Yu C, Regine WF. Comparative analyses of linac and Gamma Knife Radiosurgery for Trigeminal Neuralgia reatments: Phys. Med Biol. 50: 5217-5227, 2005.
70. Ha Jonathan, Zhang G, Naqvi SA, Regine WF, Yu CX. Feasibility of delivering grid therapy using multileaf collimator: Med. Phys. 33(1): 76-82, 2006.
71. Thomas KC, Nosyk B, Fisher CG, Dvorak Marcel, Patchell RA, Regine WF, Loblaw A, Bansback N, Guh D, Sun Huiying, Anis A. Cost-Effectiveness of Surgery Plus Radiotherapy versus Radiotherapy Alone for Metastatic Epidural Spinal Cord Compression. Int. Journal Radiation Oncology Biol. Phys. 66(4): 1212-1218, 2006.
72. Huhn JL, Regine WF, Valentino J, Meigooni, AS, Kudrimoti M, Mohiuddin M. Spatially Fractionated GRID Radiation Treatment of Advanced Neck Disease Associated with Head and Neck Cancer. TCRT, 5(6): 607-610, December, 2006.
73. Regine WF, Hanna N, Ahmed M, Garofalo MC, DeSimone P, Arnold S, Mohiuddin M. Low-dose Radiation Therapy as a Chemopotentiator of Gemcitabine in Tumors of the Pancreas/small bowel – A Phase I Study Exploring a New Treatment Paradigm. Int. Journal Radiation Oncology Biol. Phys. 68 (1): 172-177, 2007.
74. D’Souza WD, Nazareth DP, Zhang B, DeYoung C, Suntharalingam M, Kwok Y, Yu Cx, Regine WF . The Use of Gated and 4D CT Imaging in Planning for Stereotactic Body Radition Therapy. Medical Dosimetry 32 (2): 92-101, 2007.
75. Gaugler JE, Linder J, Given CW, Kataria R, Tucker G, Regine WF. Work, Gender and Stress in Family Cancer Cargiving. Support Care Cancer 16: 347-357, 2008.
76. Gaugler JE, Linder J, Given CW, Kataria R, Tucker G, Regine WF. The Proliferation of Primary Cancer Caregiving Stress to Secondary Stress. Cancer Nursing 31 (2): 1-8, 2008.
77. Balcer-Kubiczek EK, Attarpourl M, Wang Jiang Z, Regine WF. The Effect of Docetaxel (Taxotere®) on Human Gastric Cancer Cancer Cells Exhibiting Low-dose Radiation Hypersensitivity. Clinical Medicine: Oncology (2): 1-11, 2008.
78. Regine WF, Winter KA, Abrams RA, Safran H, Hoffman JP, Konski A, Benson AB, Macdonald JS, Kudrimoty MR, Fromm ML, Haddock MG, Schaefer P, Willett C, Rich TA. Fluorouracil vs Gemcitabine Chemotherapy Before and After Fluorouracil-based Chemoradiation Following Resection of Pancreatic Adenocarcinoma: A Randomized Controlled. JAMA. 2008; 299(18):1019-1026.
79. Flannery TW, Suntharalingam M, Regine WF, Chin LS, Krasna MJ, Shehata MK, Edelman MJ, Kremer M, Patchell RA, Kwok Y. Long-Term Survival in Patients with Synchronous, Solitary Brain metastasis from Non-Small-Cell Lung Cancer Treated with Radiosurgery. Int. Journal Radiation Oncology Biol. Phys. 72 (1): 19-23, 2008.
80. Berger AC, Garcia M, Hoffman JP, Regine WF, Abrams RA, Safran H, Konski A, Benson AB, MacDonald J, Willett C. Postresection CA 19-9 Predicts Overall Survival in Patients with Pancreatic Cancer Treated with Adjuvant Chemoradiation: A Prospective Validation by RTOG 9704. Journal of Clinical Oncology 26 (36): 5918-5922, December 2008.
81. Farrell, J, Regine WF, et.al. Human Equilibrative Nucleoside Transporter 1 Levels Predice Response to Gemcitabine in Patients with Pancreatic Cancer. Gastroenterology, 136(1): 187-95, January, 2009.
82. Farrell J, Garcia M, Liu A, Ammar A, Regine WF, Abrams A, Benson AB, Madonald J, Schaefer P, Yun Y, Elsaleh H. Ribonucleotide Reductase Subunit M2: Predictive of Response to Gemcitabine in Pancreatic Cancer: RTOG 9704. Gastroenterology, 136(1), Jan 2009:187-195.
83. Dhople A, Adams JR, Maggio WW, Naqvi S, Regine WF, Kwok Y. Long Term Outcomes of Gamma Knife Radiosurgery for Classic Trigeminal Neuralgia: Implications of Treatment and Critical Review of the Literature. Journal of Neurosurgery, March 2009.
84. Berlin J, Hoffman J, Regine WF. Editorial: Combined Modality Treatment of Resectable and Borderline Resectable Pancreas Cancer: Expert Consensus Statement. Annals of Surgical Oncology (16):1757- 1759, April, 2009.
85. Crane CH, Winter K, Regine WF, Safran H, Rich TA, Curran WJ, Willett CG. Phase II Study of Bevacizumab with Concurrent Capecitabine and Radiation Followed by Maintenance Gemcitabine and Bevacizumab for Locally Advanced Pancreatic Cancer: RTOG 0411. Journal of Clinical Oncology 27 (25): 4089-4095, September, 2009.
86. Gaugler JE, Linder J, Given CW, Kataria R, Tucker G, Regine WF. Cancer Caregiving and Negative Outcomes: The Direct and Mediational Effects of Psychosocial Resources. Journal of Family Nursing, 15(4) 417-444, November, 2009.
87. Mohiuddin, Ma, Regine WF. Repeat Computed Tomography Simulation to Assess Lumpectomy Cavity Volume During Whole Breast Irradiation. IJROBP, 75(3): 751-756, November, 2009.
88. D’Souza W, Malinowski K, Van Liew S, D’Souza G, Asbury K, McAvoy T, Suntharalingam M, Regine WF. Investigation of Motion-Sickness and Inertial Stability on a Moving Couch for Intra-Fraction Motion Compensation. Acta Oncologica, 48(8): 1198-1203, November, 2009.
89. Nichols EM, Dhople AA, Mohiuddin MM, Flannery TF, Yu CX, Regine WF. Comparative Analysis of the Post-Lumpectomy Target Volume Versus the Use of Pre-Lumpectomy Tumor Volume for Early Stage reast Cancer: Implications for the Future. IJROBP, 77(1): 197-202, May, 2010.
90. Blackstock AW, Russo SM, Konski AA, Suh WW, Cosman BC, Herman J, Mohiuddin, Mo., Poggi MM, Regine WF, Saltz L, Small W Jr., Zook J. Local Excision in Early Stage Rectal Cancer: Expert Panel on Radiation Onology-Rectal/Anal Cancer. [online publication]. Reston (VA): American College of Radiology (ACR); 2010. 5.p.
91. Blackstock AW, Russo SM, Konski AA, Suh WW, Cosman BC, Herman J, Mohiuddin, Mo., Poggi MM, Regine WF, Saltz L, Small W Jr., Zook J. Local Excision in Early Stage Rectal Cancer: Expert Panel on Radiation Onology-Rectal/Anal Cancer. Curr Probl Cancer. 34(3): 193-200, June 2010.
92. Mutaf YD, Nichols EM, Yu C, Prado K, Feigenberg SJ, Yi B, D’Souza WD, Regine WF. The Dosimetric Advantage of Stereotactic Radiotherapy in Partial Breast Irradiation: A Comparative Analysis. Radiotherapy and Oncology 99, S160-1 (2011).
93. Yovino S, Poppe M, Jabbour S, David V, Garofalo M, Pandya N, Alexander R, Hanna N, Regine WF. Intensity-Modulated Radiation Therapy Significantly Improves Acute Gastrointestinal Toxicity in Pancreatic and Ampullary Cancers. IJROBP, 79(1): 158-162, January, 2011.
94. Regine WF, Winter K, Abrams R, Safran H, Hoffman JP, Konski A, Benson Al B, Macdonald JS, Rich
TA, Willett CG. Fluorouracil Based Chemoradiation with Either Gemcitabine or Flourouracil Chemotherapy Following Resection of Pancreatic Adenocarcinoma: 5-Year Analysis of the US Intergroup/RTOG 9704 Phase III Trial. Ann Surg Oncol 18: 1319-1326, April 2011.
95. Szerlip N, Rutter CE, Ram N, Yovino S, Kwok Y, Maggio WW, Regine WF. Factors Impacting Volumetric White Matter Changes Following Whole-Brain Radiation Therapy. J Neurooncol (2011) 103:111–119, May 2011.
96. Mutaf YD, Nichols EM, Yu C, Prado K, Feigenberg SJ, Yi B, D’Souza WD, Regine WF. The Dosimetric Advantage of Stereotactic Radiotherapy in Partial Breast Irradiation: A Comparative Analysis. Radiotherapy and Oncology 99(1): S572, May, 2011.
97. Koshy M, Rich S, Merchant TE, Mahmood U, Regine WF, Kwok Y. Post-Operative Radiation Improves Survival in Children Younger Than 3 Years with Intracranial Ependymoma. J Neurooncol. 2011 105(3):583-90, December 2011.
98. Showalter TN, Winter K, Berger AC, Regine WF, Abrams RA, Safran H, Hoffman JP, Benson AB, MacDonald JS, Willett CG. The Influence of Total Nodes Examined, Number of Positive Nodes, and Lymph Nodes, and Lymph Node Ratio on Survival after Surgical Resection and Adjuvant Chemoradiation for Pancreatic Cancer. A Secondary Analysis of RTOG 9704.Int J. Radiation Onclogy Biol Phys., 81:(5) 1328-35, December 2011.
99. Abrams RA, Winter KA, Regine WF, Safran H, Hoffman JP, Lustig R, Konski AA, Benson AB, Macdonald JS, Rich TA, Willett CG. Failure to Adhere to Protocol Specified Radiation Therapy Guidelines Was Associated with Decreased Survival in RTOG 9704 – A Phase III Trial of AdjuvantChemotherapy and Chemoradiotherapy for Patients with Resected Adenocarcinoma of the Pancreas. Int. J. Radiation Oncology Biol.Phys., 82:809-816, 2012.
100. Neuner G, Mohiuddin MM, Vander Walde N, Goloubeva O, Ha J, Yu CX, Regine WF. High-Dose Spatially Fractionated Grid Radiation Therapy (SFGRT): A Comparison of Treatment Outcomes with Cerrobend vs. MLC SFGRT. Int. J. Radiation Oncology Biol.Phys., 82:(5)1642-49, 2012.
101. Strongin A, Yovino S, Taylor R, Wolf J, Cullen K, Ord R, Zimrin A, Strome S, Regine WF, Suntharalingam, M. Tumor Volume Predicts Tumor Control and Survival among Patients with Locally Advanced Head and Neck Cancer Undergoing Definitive Chemoradiation Therapy. Int. J. Radiation Oncology Biol.Phys., 82:(5)1823-30, 2012.
102. Neuner G, Badros AA, Meyer TK, Nanaji NM, Regine WF. Complete Resolution of Laryngeal Amyloidosis with Radiation Treatment. Head Neck 34: 748-52, May, 2012.
103. Nichols R, Huh S, Prado K, Sharma NK, Yi BY, Ho MW, Hoppe BS, Mendenahall WM, Mendenhall NP, Regine WF. Protons Offer Reduced Normal Tissue Exposure for Patients Receiving Postoperative. Radiotherapy (RT) for Resected Pancreatic Head Cancer. Int. J. Radiation Oncolgy Biol Physics., 83:(1) 158-63, May 2012.
104. Raponi M, Boeck, Isaacson J, Moore JR, Clements J, Richardson B, Towne P, Ormanns S, Kirchner T, Regine WF, Bradley F, Winter K, Rolfe L, Allen AR, Anderson R, Heinemann V, Dicker AP. Development of a Rabbit Monoclonal Antibody for Determining hENT1 Status and Predicting Response to Gemcitabine in Pancreatic Ductal Adenocarcinoma. Journal of Clinical Oncology, vol. 30, issue no. 15_suppl 4041-4041, May 2012.
105. Goodman KA, Regine WF, Dawson L, Ben-Josef E, Haustermans K, Bosch WR, Turian J, Abrams RA. RTOG Consensus Panel Guidelines for the Delineation of the Clinical Target Volume in the Postoperative Treatment of Pancreatic Head Cancer. Int. J. Radiation Oncology Biol.Phys., 83:(3)901-908, 2012.
106. Yovino S, Maidment BW, Herman J, Pandya N, Goloubeva O, Wolfgang C, Schulick R, Laheru D, Hanna N, Alexander HR, Regine WF. Analysis of Local Control in Patients Receiving IMRT for Resected Pancreas Cancer. Int. J. Radiation Oncology Biol.Phys., 83:(3)916-920, 2012.
107. Gaugler JE, Eppinger A, King J, Sandberg T, Regine WF. Coping and its Effects in Care Giving. Supportive Care in Cancer. 21:385-395, 2013.
108. Gleason JF, Kudrimoti M, Van Meter E, Mohiuddin M, Regine WF, Valentine J, Kenady D, Arnold S. Induction Low-Dose Fractionated Radiation with Concurrent Paclitasel and Carboplatin for Locally Advanced Head and Neck Cancer: 5 Year Results of a Prospective Phase II Trial. J Radiat Oncol. 1;2(1), Pages: 35-42, March 2013.
109. Mutaf Y, Zhang J, Yu CX, Yi, BY, Prado K, D’Souza W, Regine WF, Feigenberg SJ. Dosimetric and Geometric Evaluation of a Novel Stereotactic Radiotherapy Device for Breast Cancer: The Gamma Pod TM Med Phys 40 (4), April 2013.
110. Yu CX, Shao X, Zhang, Regine WF, J, Zheng M, Deng J, Duan Z. GammaPod – A New Device Dedicated For Stereotactic Radiotherapy of Breast Cancer. Med. Phys 40 (5), May, 2013.
111. Oden J, Toma-Dasu-Iuliana, Yu CX, Feigenberg SJ, Regine WF, Mutaf Y. Dosimetric Comparison between Intra Cavitary Breast Brachytherapy Techniques for Accelerated Partial Breast Irradiation and A Novel Stereotactic Radiotherapy Device for Breast Cancer: GammaPodTM. Phys. Med. Biol. 58(2013) 4409-4421, June, 2013.
112. Lu W, Neuner G, George R, Zhendong W, Sasor S, Huang X, Regine WF, Feigenberg SJ, D’Souza W. Audio-Visual Biofeedback Does Not Improve the Reliability of Target Delineation Using Maximum Intensity Projection (MIP) in 4DCT Radiotherapy Planning. doi: 10.1016/j.ijrobp.2013.10.020, Int J Radiat Oncol Biol Phys. 2014 Jan 1;88(1):229-35.
113. Neuner G, Lu, W, George R, Zhendong W, Sassor S, Regine WF, Feigenberg S, D’Souza W. Audio-Visual Feedback Does Not Improve the Reliability of Target Delineation using Maximum Intensity Projection (MIP) in 4DCT Radiotherapy Planning. IJROBP, 88(1): 229-235, January 2014.
114. Morganti A, Falconi M, Van Stiphout R, Mattiucci G, Alfieri S, Calvo F, Dubois J, Fastner G, Herman J, Maidment B, Miller R, Regine WF, Reni M, Sharma N, Ippolito E, Valentini V. Multi-institutional Pooled Analysis on Adjuvant Chemoradiation in Pancreatic Cancer. Int. J. Radiation Oncology Biol.Phys., 90:(4), Pages 911–917, November 2014.
115. Mattiucci G.C., Falconi M., Stiphout R., Alfieri S., Calvo F., Maidment III B., Miller R., Regine WF, Reni M., Sharma N., Genovesi D., Balducci M., Deodato F., Valentini V., Morganti A. Adjuvant Chemoradiation in pancreatic cancer: a pooled analysis in elderly (≥ 75 years) patients. Scopus, Anticancer Research, 35(6):, 3441-3446, June, 2015.
116. Sharma NK, Pandya N, Wong RK, Herman JM, Hanna N, Laheru D, Major P, Alexander HR, Kennedy N, Regine WF. Evaluation of Low-Dose Fractionated Radiation Therapy as a Chemopotentiator of Gemcitabine in Advanced Pancreatic Cancer: Results from an International Multi-Institutional Phase II Trial. J Radiat Oncol (2015) 4:401–409, Nov 2015.
117. Li D, Moughan J, Crane C, Hoffman JP, Regine WF, Abrams RA, Safran H, Freedman GM, Guha C, Abbruzzesel JL. RecQ1 A159C Polymorphism is Associated with Overall Survival of Patients with Resected Pancreatic Cancer: A Replication Study in RTOG 9704. Int J Radiat Oncol Biol Phys 94 (3), 554-560. 2015 Nov 2015.
118. Chuong M, Yam M, Li Z, Langen K, Huh S, Morris C, Regine WF, Mehta M, Snider J, Rutenberg M, Nichols R. Is pencil beam scanning dosimetrically advantageous compared to passively scattered proton workstherapy for unresectable pancreatic cancer? Int. J. Radiation Oncology Biol Phys, 93(3), Suppl Page E172., November, 2015.
119. Ben-Josef E., George A., Regine WF, Abrams R., Morgan M., Thomas D., Schaefer P., DiPetrillo T., Fromm M., Small W., Narayan S., Winter K., Guha C., William T. Glycogen Synthase Kinase 3 beta (GSK3) predicts survival in adenocarcinoma of the pancreas Clin Cancer Res. 21(24): 5612–5618, December 2015.
120. Chhabra A, Kaiser A, Regine WF, Chuong M. The expanding role of stereotactic body radiation therapy for pancreatic cancer: a review of the literature. Transl Cancer Res 2015;4(6):659-670, December 2015.
121. Lin J, Lin M, Hall A, Singh D, Regine WF. Comparison of Bolus Electron Conformal Therapy Plans to Traditional Electron and Proton Therapy to Treat Melanoma in the Medial Canthus. Pract Radiat Oncol. 6(2):105-9, March 2016.
122. Chang L, Moughan J, Crane C, Hoffman JP, Regine WF, Abrams RA, Safran H, Freedman G, Guha C, Abbruzzese JL, Li Donghui. RECQ1 A159C Polymorphism is Associated with Overall Survival of Patients with Resected Pancreatic Cancer: A Replication Study in RTOG 9704. Int. J. Radiation Oncology Biol.Phys., 94:(3), Pages 554-560, March 2016.
123. Hanna A, Boggs H, Kwok Y, Simard M, Regine WF, Mehta M. What Predicts Early Volumetric Edema Increase Following Stereotactic Radiosurgery for Brain Metastases? J Neurooncol 2016 Apr; Vol. 127 (2), pp. 303-11, April 2016.
124. Lin J, Diwanji T, Snider J, Knight N, Regine WF. Screening Patterns and Concerns in Caregivers of Patients Undergoing Radiation Therapy. J Oncol Pract. 2016 Apr;12(4):e405-12, April 2016.
125. Arnold S, Kudrimoti M, Dressler E, Gleason J, Silver N, Regine WF, Valentino J. Using Low-dose Radiation to Potentiate the Effect of Induction Chemotherapy in Head and Neck Cancer: Results of a Prospective Phase II Trial. Adv Radiat Oncol.14;1(4) p.252-259, July 2016.
126. Choi W, Xue M, Lane B, Kyu Kang M, Patel K, Regine WF, Klahr P, Wang J, D'Souza W, Lu W. Individually Optimized Contrast-Enhanced 4D-CT for Radiotherapy Simulation in Pancreatic Ductal Adenocarcinoma. Med Phys. 43(10), p.5659, October 2016.
127. Mishra M, Aggarwal S, Bentzen S, Knight N, Mehta M, Regine WF. Establishing Evidence-Based Indications for Proton Therapy: An Overview of Current Clinical Trials. International Journal of Radiation Oncology • Biology • Physics, Vol. 97, Issue 2, p228–235, November 2016.
128. Snider J, Mutaf Y, Nichols E, Hall A, Vadnais P, Regine WF, Feigenberg S. Dosimetric Improvements with a Novel Breast Stereotactic Radiotherapy Device for Delivery of Preoperative Partial-Breast Irradiation. Oncology, Vol. 92 (1), Pages: 21–30, November 2016.
129. Nichols EM, Kesmodel S, Bellavance E, Dragula C, Tkaczuk K, Cohen RJ, Citron W, Morgan M, Staats P, Feigenberg S, Regine WF. Preoperative Accelerated Partial Breast Irradiation for Early-Stage Breast Cancer: Preliminary Results of a Prospective Phase II Trial. International Journal of Radiation Oncology • Biology • Physics,Vol. 97, Issue 4, p. 747-753, March 2017.
130. Hepel J, Mundt A, Yashar C, Feigenberg S, Koltis G, Prasad D, Heron D, Patel S, Regine WF, Sharma N, Herbert M, Wallis N, Kuettel M. Comparison of Onsite Versus Online Chart Reviews as Part of the American College of Radiation Oncology Accreditation Program. Journal of Oncology Practice, Vol. 13, Issue 5, p516-521, May 2017.
131. Scartoni D, Giacomelli I, Regine WF, Chuong M.: Does lymphocyte-to-monocyte ratio before, during, or after definitive chemoradiation for locally advanced pancreatic cancer predict for clinical outcomes? J Gastrointest Oncol., 8(4):721–727, September 2017.
132. Remick J, Regine WF, Malyapa R, Ng V, Vyfhuis M, Diwanji T, Shyu S, Snider J. Excellent Pathologic Response and Atypical Clinical Course of High-Grade Extremity Sarcoma to Neoadjuvant Pencil Beam Scanning Proton Therapy. Cureus, Vol. 9(9), pp. e1687, September 2017.
133. Verma V, Rwigema JC, Malyapa R, Regine WF, Simone II C. Systematic Assessment of Clinical Outcomes and Toxicities of Proton Radiotherapy for Reirradiation. Radiother Oncol., 125 (1), p.21-30, September 2017.
134. Snider J, Mutaf Y, Nichols E, Hall A, Vadnais P, Regine WF, Feigenberg S. Projected Improvements in Accelerated Partial Breast Irradiation Using a Novel Breast Stereotactic Radiotherapy Device: A Dosimetric Analysis. Technology in Cancer Research & Treatment, Vol. 16(6) 1031–1037, December 2017.
135. Lawrence Y, Moughan J, Magliocco A, Klimowicz A, Regine WF, Mowat R, DiPetrillo T, Small W, Simko J, Golan T, Winter K, Guha C, Crane C, Dicker A. Expression of the DNA Repair Gene MLH1 Correlates With AQ1 Survival in Patients Who Have Resected Pancreatic Cancer and Receive Adjuvant Chemoradiation: NRG Oncology RTOG Study 9704 AQ11. Cancer, 1;124(3):491-498, February 2018.
136. Regine WF, Winter K, Abrams R, Safran H, Kessel I, Chen Y, Fugazzi J, Donnelly E, DiPetrillo T, Narayan S, Plastaras J, Gaur R, Delouya G, Suh J, Meyer J, Haddock M, Didolkar M, Padula G, Johnson D, Hoffman J, Crane C. Postresection CA19-9 and margin status as predictors of recurrence after adjuvant treatment for pancreatic carcinoma: Analysis of NRG oncology RTOG trial 9704. Advances in Radiation Oncology, 3(2), p154-162, June 2018.
137. Chuong M, Yam M, Li Z, Langen K, Huh S, Morris C, Regine WF, Mehta M, Snider J, Rutenberg M, Nichols R. Pencil beam scanning versus passively scattered proton therapy for unresectable pancreatic cancer. J Gastrointest Oncol., 9(4), p. 687-693, August 2018.
138. Chiaramonte D, Kaiser A, McMath G, Simone C, Berman B, Regine WF. Integrative Wellness for Patients Receiving Proton Therapy: A Patient-Centered Collaboration. Journal of Alternative and Complementary Medicine (JACM), 24(9-10):1012-1013, September 2018.
139. Nathenson M, Barysauskas C, Nathenson R, Regine WF, Hanna N, Sausville E. Surgical resection for recurrent retroperitoneal leiomyosarcoma and liposarcoma. World Journal of Surgical Oncology, 16(1):203, October 2018.
140. Rice S, Bentzen S, Hanna A, Choi E, Boggs D, Kwok Y, Hyder J, Feigenberg S, Regine WF, Woodworth G, Eisenberg H, Yu C, Biggins T, Barnholtz-Sloan J, Sperduto P, Weltman E, Mehta M. Prognostic Models for Patients with Brain Metastases after Stereotactic Radiosurgery with or without Whole Brain Radiotherapy: A Validation Study. Neuro-Oncology, 140(2), p. 341-349, November 2018.
141. Mattiucci G, Morganti A, Farioli A, Alfieri S, Arcelli A, Bertini F, Calvo F, Cammelli S, Cellini F, Fuccio L, Giaccherini L, Guigo A, Herman J, Macchia G, Maidment III B, Miller R, Regine WF , Reni M, Sharma N, Falconi M, Valentini V. Prognostic Impact of Presurgical CA19-9 Level in Pancreatic Adenocarcinoma: A Pooled Analysis. Transl Oncol.,12(1):1-7, January 2019.
142. Sours Rhodes C, Zhang H, Patel K, Mistry N, Kwok Y, D'Souza WD, Regine WF, Gullapalli RP. The feasibility of integrating resting-state fMRI networks into radiotherapy treatment planning. J Med Imaging Radiat Sci: 50(1), 119–128, March 2019.
143. Morganti A, Cellini F, Buwenge M, Arcelli A, Alfieri S, Calvo F, Casadei R, Cilla S, Deodate F, Di Gioia G, Di Marco M, Fuccio L, Bertini F, Guido A, Herman J, Macchia G, Maidment B, Miller R, Minni F, Passoni P, Valentini C, Re A, Regine WF, Reni M, Falconi M, Valentini V, Mattiucci G. Adjuvant chemoradiation in pancreatic cancer: impact of radiotherapy dose on survival. BMC Cancer, 2019 (19): 569 – 579, June 2019.
144. Remick J, Bentzen S, Simone C, Nichols E, Suntharalingam M, Regine WF. The Downstream Effect of a Proton Treatment Center on an Academic Medical Center. Int J Radiat Oncol Biol Phys., Vol 104, Issue 4, p. 756–764, July 2019.
145. Sharma A, Khairnar R, Kowalksi E, Remick J, Nichols E, Mohindra P, Yock T, Regine WF, Mishra M. Patient prioritization for proton beam therapy in a cost-neutral payer environment: use of a clinical benefit score for resource allocation. Cureus 11(9): p. 5703 - 5715, September 2019.
146. Reyngold M, Winter K, Regine WF, Abrams R, Safran H, Hoffman J, Mowat R, Hayes J, Kessel I, Petrillo T, Narayan S, Chen Y, Ben-Josef E, Meyer J, Haddock M, Feldman M. Marital Status and Overall Survival in Patients with Resectable Pancreatic Cancer? Results of an Ancillary Analysis of NRG Oncology/RTOG 9704. The Oncologist Vol 24, Issue 12, p. 1–7, December 2019.
147. Abrams RA, Winter KA, Safran H, Goodman KA, Regine WF, Berger AC, Gillin MT, Philip PA, Lowy AM, Wu A, DiPetrillo TA, Corn BW, Seaward SA, Haddock MG, Song S, Jiang Y, Fisher BJ, Katz AW, Mehta S, Willett CG, Crane CH. Results of the NRG Oncology/RTOG 0848 Adjuvant Chemotherapy Question—Erlotinib+Gemcitabine for Resected Cancer of the Pancreatic Head: A phase II randomized clinical trial. American Journal of Clinical Oncology, Vol 43 (3), p. 173-179, March 2020.
148. Remick J, Kowalski E, Khairnar R, Sun K, Morse E, Cherng H, Poirier Y, Lamichhane N, Becker S, Chen S, Patel A, Kwok Y, Nichols E, Mohindra P, Woodworth G, Regine WF, Mishra M. A multi-center analysis of single-fraction versus hypofractionated stereotactic radiosurgery in the treatment of brain metastasis. Clinical Radiation Oncology Journal, Vol 15, Article number: 128 (2020), May 2020.
149. DeCesaris C, McCarroll R, Mishra M, Glass E, Greenwald B, Carr S, Burrows W, Mehra R, Regine WF, Simone C, Choi J, Molitoris J. Assessing Outcomes of Patients Treated with Re-irradiation Utilizing Proton Pencil-Beam Scanning for Primary or Recurrent Malignancies of the Esophagus and Gastroesophageal Junction. Journal of Thoracic Oncology, Vol 16, Issue 6, p. 1054-1064, June 2020.
150. Griffin R, Ahmed M, Amendola B, Belyakov O, Bentzen S, Butterworth K, Chang S, Coleman N, Djonov V, Formenti S, Eli Glatstein E, Guha C, Kalnicki S, Le Q, Loo B, Mahadevan A, Massaccesi M, Maxim P, Mohiuddin Ma, Mohiuddin Mo, Mayr N, Obcemea C, Petersson K, Regine WF, Roach M, Romanelli P, Simone C, Snider J, Spitz D, Vikram B, Vozenin M, Abdel-Wahab M, Welsh J,Wu X, Limoli C. Understanding High-Dose, Ultra-High Dose Rate, and Spatially Fractionated Radiation Therapy. Int J Radiat Oncol Biol Phys., Vol 107, Issue 4, p. 766–778, July 2020.
151. Kowalski E,Remick J, Khairnar R, Sun, K, Morse E, Cherng H, Poirier Y, Lamichhane N, Becker S, Chen S, Molitoris JK, Kwok Y, Regine WF, Mishra M. Immune Checkpoint Inhibition in Patients Treated with Stereotactic Radiation for Brain Metastases. (Accepted to Radiation Oncology, RAON-D-20-00331R1, August 2020).
152. Bitterman D, Winter K, Hong T, Fuchs C, Regine WF, Abrams R, Safran H, Hoffman J, Benson A, Kasunic T, Mulcahy M, Srauss J, DiPetrillo T, Stella J, Chen Y, Plastaras J, Crane C. Impact of diabetes and insulin use on prognosis in patients with resected pancreatic cancer: an ancillary analysis of NRG Oncology RTOG 9704. Int J Radiat Oncol Biol Phys, S0360-3016(20)34137-7, August 2020.
153. DeCesaris C, Berger M, Choi I, Carr S, Burrows W, Regine WF, Simone III C, Molitoris J. Pathologic complete response (pCR) rates and outcomes after neoadjuvant chemoradiotherapy with proton or photon radiation for adenocarcinomas of the esophagus and gastroesophageal junction. Journal of Gastrointestinal Oncology, Vol 11, Issue 4, p. 663–673, August 2020.
154. Koroulakis A, Molitoris J, Kaiser A, Hanna N, Bafford A, Jiang Y, Bentzen S, Regine WF. Proton Re-irradiation for Rectal Cancer: A Single Institutional Experience. (Accepted to Advances in Radiation Oncology, Ms. No. ADVANCESRADONC-D-20-00279R1, October 2020).
155. Sood A, Bivona L, Mahkzoumi Z, Hausner P, Miller K, Regine WF, Snider J, Ng V. Beyond the dermis-high-risk invasive squamous cell carcinoma: a retrospective review. Journal of Wound Care, Vol 29, Issue 10, p. 556-561, October 2020.
156. Snider J, Molitoris J, Shyu S, Diwanji T, Rice S, Kowalski E, Decesaris C, Remick J, Yi B, Zhang B, HallA, Hanna N, Ng V, Regine WF. Spatially Fractionated Radiotherapy (GRID) Prior to Standard Neoadjuvant Conventionally Fractionated Radiotherapy for Bulky, High-Risk Soft Tissue and Osteosarcomas: Feasibility, Safety, and Promising Pathologic Response Rates. Radiation Research, Vol. 194, Issue 6, p. 707–714, October 2020.
157. Arons D, Alexander G, Koroulakis A, Zakhary M, Molitoris J, Miller R, Regine WF, Witek M. Time to Treatment Analysis of Head and Neck Cancer Patients Undergoing Proton Therapy. Am J Otolaryngol Head Neck Surg, Volume 4, Issue 1, article 1116, January 2021.
158. Rao A, Sun K, Zhu M, Mossahebi S, Sabouri P, Houser T, Jatczak J, Zachary M, Regine WF, Miller R, Bentzen S, Mishra M. Plan Quality Effects of Maximum Monitor Unit Constraints in Pencil Beam Scanning Proton Therapy for Central Nervous System and Skull Base Tumors. Radiother Oncol., S0167-8140 (21) 06142-9, March 2021.
INVITED SUBMISSIONS/LETTERS/CASE REPORTS:
1. Regine WF, Ayyangar K, Komarnicky LT, Bhandare N, Mansfield CM. To Boost, Why and How. Int J Radiat Oncol Biol Phys 20(1): 179, 1991. [Letter]
2. Mohiuddin M, Regine WF, Rosato F, Barbot D, Schuricht A, Biermann W, Cantor R. A Comparison of Intraoperative Radiation Therapy (IORT) and I-125 Implantation for Cancer of the Pancreas. Proceedings of the 4th International Symposium on Intraoperative Radiation Therapy: 315-323, 1994.
3. Regine WF, Kun LE. Retrospective Results Need Prospective Confirmation. Int J Radiat Oncol Biol Phys 31(3): 681, 1995. [Letter]
4. Regine WF, Kramer CK. To Boost or Not to Boost? . . . It’s Not the Only Question! Int J Radiat Oncol Biol Phys 32(1):273 1995. [Letter]
5. Regine WF, Mohiuddin M. Extrahepatic Biliary Duct Carcinoma: the Continuing Evolution of Multidisciplinary Management. Int J Radiat Oncol Biol Phys 34(4): 963-964, 1996.
6. Regine WF, Mohiuddin M. Does Neck Stage Predict Local Control After Irradiation for Head and Neck Cancer Oncology 10(3):384-386, 1996.
7. Regine WF, John WJ, Mohiuddin M. Current and Emerging Treatments for Pancreatic Cancer. Drugs & Aging 11(4): 285-295, 1997.
8. Regine WF, Abrams RA. Adjuvant Therapy for Pancreatic Cancer: Back to the Future. Int J Radiat Oncol Biol 42(1): 59-63, 1998.
9. Regine WF, John WJ, Mohiuddin M. Evolving Trends in the Combined Modality Therapy for Pancreatic Cancer. J of Hepatobiliary Pancreat Surg 5(3): 227-234, 1998.
10. Regine WF, John WJ, Mohiuddin M. Adjuvant Therapy for Pancreatic Cancer: Current Status. Frontiers in Bioscience 3: 186-192, 1998.
11. Patchell RA, Tibbs PA, Regine WF, Mohiuddin M, Kryscio RJ, Markesbery WR, Foon KA, Young B, Dempsey RJ. Postoperative Radiotherapy for Single Brain Metastases. JAMA 281(18): 1696, 1999. [Letter]
12. Mohiuddin M, Regine WF, Mohiuddin Ma, Marks G. Defining the Multiple Modality Approach to the Treatment of Cancer of the Rectum. JAMA 31: 217-221, 1999.
13. Regine WF, The Radiation Oncologist’s Perspective on Stereotactic Radiosurgery. TCRT 1(1): 43-49, 2002.
14. Regine WF, Sperduto PW, Scott CB, Mehta, MP. What is the Appropriate Primary Endpoint for Clinical Trials for Patients With Brain Metastases. Int J Radiat Oncol Biol Phys 53(5):1394, 2002.
15. Kenady DE, Arnold SM, Regine WF, Mentzer RM. Oral/Pharyngeal Squamous Carcinoma: Treatment Strategies. Journal of KMA 100: 318-324, 2002.
16. Regine WF, Stereotactic Radiosurgery – State of the Art. Tech Ca Res Treat 2(2):77-78, 2003.
17. Willett CG, Safran H, Abrams RA, Regine WF, Rich TA, and the Gastrointestinal Committee of the RTOG. Clinical Research in Pancreatic Cancer: The Radiation Therapy Oncology Group Trials. Int J Radiat Oncol Biol Phys 56(4):31-37, 2003.
18. Sloan AE, Arnold SM, St Clair WS, Regine WF. Brain Injury: Current Management and Investigations. Sem in Rad Onc 13(3):309-321, 2003.
19. St. Clair WS, Arnold SM, Sloan AE, Regine WF. Spinal Cord and Peripheral Nerve Injury: Current Management and Investigations. Sem in Rad Onc 13(3):322-332, 2003.
20. Garofalo M, Kwok Y, Regine WF. The Evolving Role of Postoperative Adjuvant Radiation Therapy for Pancreatic Cancer, Surg Oncol Clin N Am 13:589-604, 2004.
21. Kwok Y, Patchell RA, Regine WF. Radiation Therapy Alone for Spinal Cord Compression: Time to Improve Upon a Relatively Ineffective Status Quo. J Clin Oncol 23:3308-3310, 2005.
22. Patchell RA, Tibbs PA, Regine WF. Surgical Resection in Metastatic Spinal Cord Compression. Lancet 366 643-648, 2005. [Letter]
23. Kwok Y, DeYoung C, Garofalo MC, Dhople A, Regine WF. Radiation Oncology Emergencies. Hematology/Oncology Clinics of North America 20: 507-522, 2006.
24. Garofalo MC, Tan MT, Regine WF. On Statistical Reanalysis, the EORTC Trial is a Positive Trial for Adjuvant Chemoradiation in Pancreatic Cancer. Annals of Surgery 244: 332-333, 2006.
25. Regine WF, Abrams RA. Adjuvant Therapy for Pancreatic Cancer: Current Status, Future Directions. Seminars in Oncology 33: (6) (S10-S13), 2006.
26. Patchell RA, Regine WF, Loeffler JS, Sawaya R. Radiosurgery Plus Whole-Brain Radiation Therapy for Brain Metastasts. JAMA 296: (17) 2006. [Letter].
27. Garofalo, MC, Abrams RA, Regine WF. Review of “Adjuvant Therapy for Pancreatic cancer – To Treat or Not to Treat?” Oncology 21: (6) May 2007. [Editorial]
28. Garofalo MC, Nichols EM, Regine WF. Optimal Adjuvant Therapy for Resected Pancreatic Cancer: Chemotherapy or Chemoradiotherapy. Proceedings of Journal of the International Society of Gastrointestinal Oncology 1(5)182 - 186, September 2007.
29. Regine WF, Winter KA, Safran H. Further discussion of Phase III Adjuvant Pancreas U.S.
30. Intergroup/Radiation Therapy Oncology Group Trial 9704. JAMA [Letter] In Press.
31. Berlin J, Hoffman J, Regine, WF. Combined Modality Treatment of Resectable and Borderline Resectable Pancreas Cancer: Expert Consensus Statement by Abrams, et al. Annals of Surgical Oncology [Editorial] Accepted 1/09.
32. Berger AC, Hoffman JP, Winter K, Regine WF, Safran H, Abrams R, Willet C. Reply to Editorial Comment of CD Atkins. J Clin Oncol. 2009; 27(15) 2753.
33. Mohiuddin MM, Regine WF. Consenting the Patient with Early Stage Breast Cancer: “Informed” Only after Multi-Disciplinary Evaluation. Journal of Clinical Oncology 27(30) 158-159, October 2009.
34. Mahmood U, Kwok Y, Regine WF, Patchell RA. Whole-Brain Irradiation for Patients with brain Metastases: Still the Standard of Care. Lancet 11, 221-222, 2010 [Letter].
35. Nichols E, Regine WF, Feigenberg S. What is the Target Volume for Pre-operative Accelerated Partial Breast Irradiation (APBI)? [Letter] Int J Radiat Oncol Biol Phys 2010;80 (1)315-316.
36. Regine WF, Ryu S, Chang EL. Spine Radiosurgery for Spinal Cord Compression: The Radiation Oncologist’s Perspective. Journal of Radiosurgery and SBRT, Vol 0 1-7, 2011.
37. Sharma N, Regine WF, Radiation Therapy in Resectable/Resected Pancreatic Adenocarcinomas: Clearing Up the Fog. Commentary, Oncology, Vol 25, No. 8, July, 2011.
38. Chuong M, Boggs D, Patel K, Regine WF, Adjuvant chemoradiation for pancreatic cancer: what does the evidence tell us? Journal of Gastrointestinal Oncology, Vol 5, No. 3, June 2014.
39. Mehta M, Langen K, Regine WF, Expanding the Horizons Of Proton Beam Therapy. Invited editorial. The Cancer Letter, Issue 31 – August 1, 2014
40. Chuong M, Mehta, MP, Langen K, Regine WF. Is Proton Beam Therapy Better Than Standard Radiation Therapy? Clinical Advances in Hematology & Oncology, Volume 12, Issue 12, Pages: 861-869, December 2014.
41. Lin J, Lin M, Hall A, Singh D, Regine WF. Comparison of Bolus Electron Conformal Therapy plans to Traditional Electron and Proton Therapy to Treat Melanoma in the Medial Canthus. Practical Radiation Oncology (2016) Issue 6, Pages: 105-109, March 2016.
42. Badiyan S, Regine WF, Mehta M. Stereotactic Radiosurgery for Treatment of Brain Metastases. Journal of Oncology Practice, Vol. 12, Issue 8, p703-713, August 2016.
43. Molitoris J, Edelman M, Regine WF, Feigenberg S. Whole Brain Radiation in the Treatment of Brain Metastases in ALK Positive Non Small Cell Lung Cancer. Journal of Clinical Oncology, Volume 35, Issue 7, Pages 809-810, March 2017.
44. Badiyan S, Molitoris J, Chuong M, Regine WF, Kaiser A. The Role of Radiation Therapy for Pancreatic Cancer in the Adjuvant and Neoadjuvant Settings. Surgical Oncology Clinics of North America, Volume 26, Issue 3, Pages 431–453, July 2017.
45. Tsai A, Vyfhuis M, Francis M, Burke A, Regine WF. Radiation-Induced Undifferentiated Pleomorphic Sarcoma of the Heart: A Teaching Case. Practical Radiation Oncology (PRO), Apr;8(2):136-139, March 2018.
46. Heron D, Suntha N, Winkfield K, Regine WF. Obituary: Carl Mansfield, MD, ScD, FACR, FASTRO (1928-2018). Int J Radiat Oncol Biol Phys, Volume 101, Issue 4, Pages 765–766, July 2018.
47. Yu N, Sio T, Mohindra P, Regine WF, Miller R, Mahajan A, Keole S. The Insurance Approval Process for Proton Beam Therapy Must Change: Prior Authorization Is Crippling Access to Appropriate Healthcare. Int J Radiat Oncol Biol Phys 104 (4), Pages 737-739, July 2019.
ABSTRACTS (Manuscript not Published):
1. Regine WF, O'Hara MD, Mohiuddin M. Murine Bone Marrow Macrophage Colony Forming Units Response to Radiation +40-420C: Potential Implications for Combined Total Body Irradiation and Hyperthermia. Int J Radiat Oncol Biol Phys 21:202-203, 1991.
2. O'Hara MD, Pollard M, Wheatley G, Regine WF, Mohiuddin M, Leeper D. Thermal Response and Hyperthermic Radiosensitization of SCID Mouse Bone Marrow CFU-C. Int J Radiat Oncol Biol Phys 27: 225, 1993.
3. Mohiuddin Me, Mohiuddin Ma, Patel N, Dey S, Chendil D, Regine WF, Mohiuddin Mo, Ahmed MM. 5-FU Sensitizes Radiation by a Mechanism Independent of p53 to Cause Clonogenic Inhibition and Apoptosis in Pancreatic Tumor Cell Lines. Int J Radiat Oncol Biol Phys 42(S2): 236(#2018), 1998.
4. Kudrimoti M, Regine WF, John W, McGrath P, Hanna N, Mohiuddin M. Concurrent Infusional Gemcitabine and Radiation in the Treament of Advanced Unresectable GI Malignancy: A Phase I/II Study. Proceedings of ASCO, J Clin Oncol 18: 242a(#928), 1999.
5. Regine WF. Non – Invasive Treatment for Acoustic Neuromas. Physician’s Practice Digest 9(3): A3, 1999.
6. Regine WF, Young AB. Gamma Knife Radiosurgery Now an Option for More Patients. Physician’s Practice Digest 9(6): A4-5, 1999.
7. Mohiuddin M, Kudrimoti M, Regine WF, McGrath P, Hanna N, Meeker T, John W. Concurrent Infusional Gemcitabine and Radiation in the Treament of Advanced Unresectable GI Malignancies. Int J Radiat Oncol Biol Phys 45(S3):255(#204), 1999.
8. Staryszak M, Meigooni AS, Drogin A, Gearheart D, Meade J, Sanders M, Young B, Regine WF. Measurement of Dose to the Normal Tissue for Treatment with Multiple Targets Using Radiosurgery Techniques. Scientific program LINAC Radiosurgery – 1999 Meeting, 58, 1999.
9. Regine WF. The Role of Radiotherapy in Colorectal Cancer. Proceedings of the 4th Annual National VA Oncology Symposium, VHSJ 5(7): 21-22, 2000.
10. Regine WF. The Radiation Oncologist’s Perspective on Stereotactic Radiosurgery. Proceedings of International Conference on Technology in Cancer Research and Treatment in the New Millennium 15-16, 2001.
11. Radiation Therapy (SFR) in the Palliation of Large Bulky (>8 cm) Melanomas. Int J Radiat Oncol Biol Phys 54 (S1), p.342 (#2225), 2002.
12. Kwok Y, Murali N, Chin L, Bangalore M, Amin P, Regine WF. Long-Term Results of Gamma Knife. Stereotactic Radiosurgery for Non-Functioning Pituitary Adenomas. Proceedings of ASTRO, Int J Radiat Oncol Biol Phys 60(1) S551 (#2361), 2004.
13. Kudrimoti M, Mohiuddin M, Ahmed M, Meigooni AS, Hanna N, Regine WF, Huhn J. Use of High Dose Spatially Fractionated Radiation (GRID Therapy) in Management of Large, Poor Prognostic Stage III (>10cms) Soft Tissue Sarcomas. Proceedings of ASTRO, Int J Radiat Oncol Biol Phys 60(1) S575 (#2400), 2004.
14. Dhople AA, Kwok Y, Jaboin J, Sorkin JD, Slawson R, Amin P, Chin LS, Regine WF. Efficacy and Quality of Life in Patients with Atypical Trigeminal Neuralgia Treated with Gamma-Knife Stereotactic Radiosurgery. Proceedings of ASTRO, Int J Radiat Oncol Biol Phys 63(2) S106 (#175), 2005.
15. Garofalo MC, Winter K, Regine WF, Rich TA, Komaki R, Tepper JE, Gunderson LL, Willett CG. Recursive Partitioning Analysis (RPA) of Prognostic Factors in Six Radiation Therapy Oncology Group (RTOG) Trials of Chemoradiotherapy for Unresectable Pancreatic Cancer. Proceedings of ASTRO, Int J Radiat Oncol Biol Phys 66(3) S80, (# 144), 2006.
16. Kudrimoti MR, Warren G, Valentino J, Spring P, Brill Y, Given C, St. Clair W, Mohiuddin M, Regine WF, Arnold S. Stratification of Therapy Basd on Response to Novel Induction Therapy in Stage III/IV Squamous Cell Carcinoma of the Head/Neck (SCCA H/N). Proceedings of ASTRO, Int J Radiat Oncol Biol Phys 66(3) S442, (# 2417), 2006.
17. Arnold SM, Warren GW, Valentine J, Brill Y, Regine WF, Spring P, Given C, Mohiuddin M, Huhn JL, Kudrimoti M. Long Term Results of Regional Control in Stage III-IV Node Positive Patients with Squamous Cell Carcinoma of the Head an Neck Using Hyperfractionated Radiation Therapy and Intraarterial Chemotherapy (HYPERRADPLAT). Proceedings of ASTRO, Int J Radiat Oncol Biol Phys 66 (3)S446, (# 2427), 2006.
18. Garofalo MC, Nazareth DP, Errens M, DSouza WD, Regine WF. A Comparison of 3D-CRT and IMRT Planning for Patients with T3N or T4Nx or T4Nx Mid/Distal Rectal Cancers: Potential for Small Bowel Sparing and Reductions in Dose-limiting Acute GI Toxicity. Proceedings of ASTRO, Int J Radiat Oncol Biol Phys 72 (1) S250, (# 2179), 2008.
19. TP Diwanji, Dhople AA, Chin LS, Maggio WW, Adams JR, Regine WF, Kwok Y. Long-term Outcome of Gamma Knife Stereotactic Radiosurgery for Multiple Sclerosis Associated Trigeminal Neuralgia. Proceedings of ASTRO, Int. J. Radiat Oncol Biol Phys 78 (8) S262 (#2134) 2010.
20. Sharma NK, Pandya N, Wong R, Herman J, Hanna NN, Laheru DA, Major P, Alexander HR, Kennedy N, Regine WF. Low Dose Upper Abdominal Radiation Therapy (LD-UART) Potentiates Gemcitabine in Patients with Advanced, Unresectable Pancreatic Cancer (PC): Final Results from a Phase II Multi-Institutional Study. Proceedings of ASTRO, Int. J. Radiat Oncol Biol Phys 78 (8) S105 (#220) 2010.
21. Neuner GA, Lu W, Wang Z, Sassor S, George R, Feigenberg SJ, Regine WF, D’Souza WD. Biofeedback During 4D-CT Image Acquisition Does not Enhance the Reliability of ITVMIP for Radiation Treatment Planning of Thoracic and Abdominal Malignancies: A Prospective Trial. Proceedings of ASTRO, Int. J. Radiat Oncol Biol Phys 78 (8) S673 (#3046) 2010.
22. Lu W, Neuner G, Wang Z, George R, Wu J, Sassor S, Regine WF, Feigenberg SJ, D’Souza WD. Evaluating Inter-fraction Variations in Tumor Volumes with Repeated 4D-CT. Proceedings of ASTRO, Int. J. Radiat Oncol Biol Phys 78 (8) S746 (#3215) 2010.
23. Lu W, Neuner G, Wang Z, George R, Wu J, Sassor S, Regine WF, Feigenberg S, D’Souza WD. Evaluating Inter-Fraction Variations in Tumor Volumes with Repeated 4D CT. IJROBP, 78(3): S748-S749, November, 2010.
24. Feigenberg SJ, Buras R, Dragula C, Citron W, Dolgovskij A, Marter K, Nichols EM, Dhople A, Tkaczuk, Regine WF. Preliminary Results of a Prospective Feasibility Study Testing Preoperative Accelerated Partial Breast Radiotherapy (APBI) Using 3 Dimensional Conformal Radiotherapy (3D CRT). Proceedings of ASTRO, J. Radiat Oncol Biol Phys 81 (2) S264 (#2108) 2011.
25. Sharma NK, Mahmood U, Horiba NM, Hanna NN, Alexander HR, Pandya NB, Regine WF. Effects of Racial/Social Factors and INT-0116/MAGIC Trials Publication on Radiation Therapy (RT) Utilization for Gastric Cancer. Proceedings of ASTRO, J. Radiat Oncol Biol Phys 81 (2) S327 (#2239) 2011.
26. Nichols EM, Grabowski SF, Hanlon A, Regine WF, Patel R, Kudryasheva S, Moeslein FM, Garofalo M, Amin PP, Sharma NK. Persormance Status (PS), Number of Lesions and Interval from Metastatic Diagnosis to Treatment (IMDTT) Predict for Overall Survival (OS) in Patients Treated With Hepatic Transarterial Radioembolization (TARE) with Yttrim-90 (Y90) Microspheres. Proceedings of ASTRO, J. Radiat Oncol Biol Phys 81 (2) S46 (#2281) 2011.
27. Grabowski SF, Nichols EM, Kudryasheva S, Patel R, Garofalo M, Amin PP, Moeslein FM, Regine WF, Sharma NK. The Efficacy of Selective Internal Radiation Therapy (SIRT) With Yttrium-90 (Y90) is Enhanced When Given in Low Volume Disease and in Conjunction With Other Liver-Directed Therapies. Proceedings of ASTRO, J. Radiat Oncol Biol Phys 81 (2) S353 (#2296) 2011.
28. Boeck S, Rapone M, Richardson B, Towne P, Isaacson J, Moore JR, Powell E, Clements J, Feng J, McElhinny A, Ormanns S, Kirchner T, Regine WF, Winter K, Ansari D, Rolfe L, Allen AR, Anderson R, Heinemann V, Dicker AP. Development of the SP 120 Rabbit Monoclonal Antibody for Determining hENT1 Status & Predicting Response to Gemcitabine in Pancreatic Ductal Adenocarcinoma. Abstract Number: 4041, Citation: J Clin Oncol 30, 2012 (suppl: abstr 4041).
29. Raponi M, Boeck S, Richardson B, Towne P, Isaccson J, Ranger-Moore J, Clements J, Feng J.D., Bartosiewicz M, Mann E, Voong C, McElhinny A, Omanns S, Kirchner T, Regine WF, Winter K, Ansari D, Rolfe L, Allen AR, Anderson R, Heinemann V, Dicker AP, Ikdahl T, Poplin E. Two-thirds Of Pancreatic Ductal Adenocarcinomas (PDAC) Have Low Expression of hENT1 as Determined by The SP120 Rabbit Monoclonal Antibody Immunohistochemistry Test. Abstract Number: 4041 Citation: J Clin Oncol 30, 2012 (suppl; abstr 4041).
30. Williams TM, George A, Regine WF, Thomas DG, Schaefer P, Safran H, Small W, Guha C, Ben-Josef, E. Caveolin-1 Expression Correlates With Outcomes in Pancreatic Ductal Carcinoma: A Secondary Analysis of RTOG 9704. IJROBP, 84,(3S): S26, November, 2012.
31. Feigenberg SF, Staats P, Citron W, Dragula C, Cohen R, Kesmodel S, Bellavance E, Chumsri S, Tkaczuk K, Regine WF. Near 25% Complete Pathologic Response Following Preoperative Accelerated Partial Breast Radiation Therapy (APBI) Using 3-dimensional Conformal Radiation Therapy (3D CRT). IJROBP, 84(3S):S238, November, 2012.
32. Feigenberg SJ, Christenson E, Staats P, Webb T, Chumsri S, Tkaczuk K, Nichols E, Kesmodel S, Bellavance E, Regine, WF. Preoperative Accelerated Partial Breast Irradiation is Associated with Decreased Cd8+ Cells with Early Breast Cancer. IJROBP, 84, (3S): S243, November, 2012.
33. Reese AS, Yang X, Lu W, Sharma NK, Feigenberg SJ, Regine WF, Yi BY. Deformable Image Registration as a Method to Assess Motion for Pancreatic Cancer Using 4D Computed Tomography (CT) scans. IJROBP, 84(3S): S771, November, 2012.
34. Yang X, Reese AS, Mutaf YD, Prado KL, Sharma NK, Feigenberg SJ, Regine WF, Yi BY. Dosimetric Validation of Respiratory Motion Margins for Patients with Pancreatic Cancer Using Deformable 4D Contour Propagation. IJROBP, 84(3S) S778-779, November, 2012.
35. Rutenberg M, Errens MA, Sharma N, Yang X, Yi BY, Regine WF. A Comparison Between Consensus Guidelines-Based PTVs and 4D-CT-Based PTVs for Locally-Advanced Pancreatic Cancer: Implications for Therapy. IJROBP, 87(2S):S189, October, 2013.
36. Chaudhry H, Hanlon AL, Kesmodel S, Bellavance EC, Tkaczuk K, Drogula C, Citron WK, Cohen RJ, Regine WF. A Prospective Tial of Peroperative Accelerated Partial Breast Irradiation (APBI): Predictors of Asymptomatic and Symptomatic Seroma Formation. IJROBP, 87(2S):S215-S216, October, 2013.
37. Sours C, Mistry N, Zhang H, Kwok Y, Mehta MP, Regine WF. Feasibility Study Testing the Incorporation of Resting State fMRI Dat in Raditation Therapy Planning to Limit Dose to Cognitive Function Networks in Patients With Primary Brain Tumors. IJROBP, 87(2S):S254-S255, October, 2013.
38. Chaudhry H, Ellison TA, Maidment BW, Regine WF, Alexander H, Hanna N, Wolfgang CL, Morris CG. Radiation Therapy in Pancreatic Neuroendocrine Tumors: Favorable Outcomes and Low Toxicity in a Multi-institutional Experience. IJROBP, 87(2S):S308, October, 2013.
39. Mooney K, Lasio G, Lu W, Feigenberg SJ, Regine WF, D’Souza W. An Approximate Entropy-Based Method for Prediction of 4D-CT Quality from Respiratory Signals. IJROBP, 87(2S):S386-S387, October, 2013.
40. Chaudhry H, Mutaf YD, Yu CX, Yi BY, Prado KL, D’Souza W, Regine WF, Feigenberg SJ. The Dosimetric Effect Of Tumor Size and Position in Prone Radiation Therapy of Breast Using a Novel Stereotactic Breast Irradiation Device. IJROBP, 87(2S):S748, October, 2013.
41. Heestand GM, Murphy JD, Moughan J, Regine WF, Luo J, Graber MS, Kunz PL, Fisher GA, Guha C, Mowat RB, Gaur R, Buyyounouski MK, Chen Y, Chang DT, Koong A. A Novel Biomarker Panel Examining Response to Adjuvant Pancreatic Cancer Therapy in RTOG 9704. J. Clin Oncol 32(3): Suppl, pg 176, January, 2014.
42. Hanna A, Boggs D, Kwok Y, Eisenberg H, Simard M, Woodworth, Regine WF, Mehta M. Factors Predicting for Increase in Peritumoral Edema Following Radiosurgery of Brain Metastases. Proceedings of ASTRO, IJROBP, 90(1S) S166 (#1021), September 2014.
43. Nichols EM, Drogula C, Hall A, Citron W, Cohen RJ, Mutaf Y, Morgan M, Bellevance E, Kesmodel SB, Regine WF, Feigenberg SJ. Prospective Evaluation of Preoperative 3D Conformal Accelerated Partial Breast Irradiation (3DCRT-APBI) Shows Promising Early Results. Proceedings of ASTRO, IJROBP, 90(1S) S264 (#2118), September 2014.
44. Chuong MD, Bhooshan N, Moeslein F, Horiba N, Hanna N, Alexander H, Hausner P, Regine WF, Kudryasheva S, Sharma N. Radiographic Tumor Volume Change as a Prognostic Factor for Overall Survival in Metastatic Colorectal Cancer Patients Who Received Selective Internal Radiation Therapy to the Liver Using Yttrium-90 Resin Microspheres. Proceedings of ASTRO, IJROBP, 90(1S) S379 (#2414), September 2014.
45. Bhooshan N, Sharma N, Moeslein F, Horiba M, Hausner P, Hanna N, Alexander H, Regine WF, Amin P, Kudryasheva S, Chuong MD. Pretreatment Tumor Volume as a Prognostic Factor in Metastatic Colorectal Cancer Patients Who Received Selective Internal Radiation Therapy to the Liver Using Yttrium-90-Coated Resin Microspheres. Proceedings of ASTRO, IJROBP, 90(1S) S379 (#2413), September 2014.
46. Hanna A, Boggs H, Mehta MP, Regine WF. Factors Predicting for Increase in Peritumoral Edema Following Radiosurgery. IJROBP, 90(1): Suppl 1, S166, September, 2014
47. Snider J, Mutaf Y, Feigenberg S, Hall A, Vagnais P, Regine WF, Nichols E. A Dosimetric Comparison Of a Novel Breast Stereotactic Radiotherapy (BSRT) – Device for the Delivery of Partial Breast Irradiation (PBI) VS. Intensity Modulated Radiotherapy (IMRT) PBI. IJROBP, 90(1): suppl 1 S278-279, Sepbember, 2014.
48. Snider J, Mutaf Y, Feigenberg S, Hall A, Vagnais P, Regine WF, Nichols E. Theoretical Improvements in Cosmetic Outcomes Utilizing a Novel Breast Stereotactic Radiotherapy (BSRT) – device compared to 3-Dimensional Partial Breast Irradiation Using IMRT (IMRT-PBI): A Dosimetric Analysis. IJROBP, 90(1): suppl 1, S279, September, 2014.
49. Bhooshan N., Sharma N.K., Moeslein F.M., Horiba M., Hanna N.N., Alexander H., Hausner P.F., Regine WF , Amin P.P., Kudryasheva S., Chuong M.D. Pre-treatment tumor volume as a prognostic factor in metastatic colorectal cancer patients who received selective internal radiation therapy to the liver using yttrium-90 coated resin microspheres IJROBP, 90(1): suppl 1, (S379), September, 2014.
50. Chuong M.D, Bhooshan N., Moeslein F., Horiba N., Hanna N, Alexander H, Hausner P, Regine WF, Kudryasheva S, Sharma N. Radiographic Tumor Volume Change As A Prognostic Factor For Overall Survival In Metastatic Colorectal Cancer Patients Who Received Selective Internal Radiation Therapy To The Liver Using Yttrium-90 Resin Microspheres. IJROBP, 90(1): suppl 1, (S379), September, 2014.
51. Chuong M.D, Bhooshan N, Sharma N, Moeslein F, Horiba N, Alexander H, Hausner P, Regine WF, Kudryasheva S, Yi B. Radiation Dose Versus Activity As A Prognostic Factor In Metastatic Colorectal Cancer Patients Who Received Selective Internal Radiation Therapy To The Liver Using Yttrium-90 Resin Microspheres. IJROBP, 90(1): suppl 1, (S379), September, 2014.
52. Xue M., Patel K, Regine WF, Lane B, D’Souza W, Klahr P, Lu W, Individually Optimkized Contrast-Enhancement 4D-CT for Pancreatic Adenocarcinoma in Radiotherapy Simulation. Med Phys. 41:200, 2014.
53. Nichols EM, Drogula C, Hall A, Citron W, Cohen RJ, Mutaf Y, Morgan M, Bellevance E, Kesmodel SB, Regine WF, Feigenberg SJ. Prospective Evaluation of Preoperative 3D Conformal Accelerated Partial Breast Irradiation (3DCRT-APBI) Shows Promising Early Results IJROBP, 90(1):Suppl 1, S364, September, 2014.
54. Lawrence YR, Moughan J, Magliocco A, Klimowicz A, Regine WF, Mowat RB, DiPetrillo T, Small W, Winter, K, Chandan G, Crane C, Dicker AP. Elevated Expression of Mismatch Repair Enzyle MLH1 Is Associated with Prolonged Overall Survival in Resected Pancreatic Cancer Treated with Adjuvant Chemoradiation, a Biomarker Analysis of RTOG 9704. American Association for Cancer Research, 73 (Suppl 8): 3553, November, 2014
55. Xu V, Choi E, Hanlon A, Regine WF, Chuong M. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios at the time of chemoradiation significantly predict for survival in resected pancreatic cancer patients. Journal of Clinical Oncology 33, no.3 suppl, p. 452-452, January 2015.
56. Yu C, Mutaf Y, Regine WF, Feigenberg S, Nichols E, Hoban P. GammaPod: A Dedicated Device for External Beam Breast Cancer SBRT in the Prone Position. Int. J. Radiation Oncology Biol Phys., Volume 93 (3), suppl, p. E586–E587, November 2015.
57. Nathenson M, Nathenson RA, Hanna N, Regine WF, Bhatnagar V, Chuong M D, Snider J III, Sausville EA. Soft tissue sarcomas in the general and referral population: the University of Maryland Medical Center experience. J Clin Oncol vol 33, no. 3 suppl, p.452-452, November, 2015.
58. Edwards JM, Shah P, Huhn J, Regine WF, Mohiuddin M, Kudrimoti MR. Definitive GRID and fractionated radiation in bulky head and neck cancer associated with low rates of distant metastasis. Int. J. Radiation Oncology Biol Phys. 93(3), Suppl Page E334., November, 2015.Snider JW III, Hall Andrea, Vadnais P, Regine WF, Nichols EM, Feigenberg SJ, Mutaf Y. Projected Improvements in Clinical Outcomes Utilizing a Novel Breast Stereotactic Radiotherapy (BSRT(-Device for Neoadjuvant partial Breast Irradition (PBI). Int. J. Radiation Oncology Biol Phys., 93(3), Suppl Page E623–E624, November 2015.
59. Snider JW III, Mutaf Y, Hall A, Vadnais P, Aggarwal S, Regine WF, Nichols EM, Feigenberg SJ. Dosimetric Improvements Based on Vacuum-Assisted Breast Immobilization Utilized with a Novel Breast Stereotactic Radiotherapy (BSRT)-Device. Int. J. Radiation Oncology Biol Phys., 93(3), Suppl Page E53, November 2015.
60. Hyder J, Bentzen S, Hanna A, Choi E, Boggs D, Kwok Y, Feigenberg S, Woodworth G, Regine WF, Barnholtz-Sloan J, Weltman E, Sperduto P, Mehta M. Prognostic Models for patients with brain metastases treated with stereotactic radiosurgery with or without whole brain radiotherapy Int. J. Radiation Oncology Biol Phys, 93(3), Suppl Page E104., November, 2015.
61. Rana Z, Snider JW, Regine WF, The Effect of Planning Target Volume on Acute Gastrointestinal Toxicity Following Intensity-Modulated Radiation Therapy. Int. J. Radiation Oncology Biol Phys, 93(3), Suppl Page E176, November 2015.
62. Ben-Josef E., George A., Regine WF, Abrams R., Morgan M., Thomas D., Schaefer P., DiPetrillo T., Fromm M., Small W., Narayan S., Winter K., Guha C., William T. Glycogen Synthase Kinase 3 Beta Predicts Survival in Resected Adenocarcinoma of the Pancreas. Clin Cancer Res 21(24), p. 5612 – 5618, December, 2015.
63. Molitoris J, Brown C, Chen S, Marter K, Spaeth K, Regine WF, Chuong M. Two Arc Volumetric Modulated Arc Therapy (VMAT) Provides Dosimetric Advantages for Stereotactic Body Radiotherapy (SBRT) for Locally Advanced Pancreatic Cancer (LAPC). Journal of Clinical Oncology 34 (4), suppl, p.445-445, February 2016.
64. Zhu M, Yam M, Mehta M, Regine WF, Langen K. A Robust Treatment Planning Technique for Proton Pencil Beam Scanning Cranial-Spinal Irradiation. Medical Physics, The International Journal of Medical Physics Research and Practice, Volume 43 (6), Part 15, p. 3505-3505, June 2016.
65. Mutaf Y, Niu Y, Yi B, Yu C, Becker S, Mossahebi S, Nichols E, Feigenberg S, Prado K, Regine WF. Commissioning of the First Clinical Stereotactic Breast Radiotherapy Device: GammaPodTM (Submitted for AAPM 2016). International Journal of Radiation Oncology Biology Physics, Volume 96, Issue 2, Supplement, Pages E640–E641, October 2016.
66. Frank SJ, Garden AS, Blanchard P, Busse PM, Gunn GB, Morrisson W, Fuller CD, Phan J, Rosenthal DI, Lin A, Regine WF, Lee NY, Parvathaneni U, Hernandez M, Teferra MY, Lee JJ, Foote R. Insurance approval, a major challenge for accruing patients to a randomized controlled trial of proton versus photon therapy in patients with oropharyngeal cancer. Oral presentation: PTCOG-NA's 2016 Annual Meeting in Memphis, TN, October 23-26, 2016.
67. Hong T, Winter K, Fuchs C, Regine WF, Abrams R, Safran H, Hoffman J, Benson A, III, MacDonald J, Kasunic T, Strauss J, DiPetrillo T, Stella P, Chen Y, Burger R, Crane C. Evaluating associations of diabetes, insulin use, and BMI with efficacy in patients with resected pancreatic cancer: an ancillary analysis of NRG Oncology/RTOG 9704. Journal of Clinical Oncology 35 (4), suppl, p.369-369. March 2017.
68. Morganti A, Cellini F, Mattiucci G, Arcelli A, Bertini F, Alfieri S, Calvo F, Casadei R, Cilla S, Deodato F, Gioia G, Di Marco C, Fariolo A, Fuccio L, Guido A, Herman J, Macchia G, Maidment III B, Miller R, Minni F, Regine WF, Reni M, Falconi M, Velentini V. Adjuvant Chemoradiation in Pancreatic Cancer: Impact of Radiotherapy dose on survival. Radiotherapy and Oncology, V.123, Suppl 1, p. S225-S226, May 2017.
69. Feigenberg S, Nichols E, Regine WF, Mutaf Y, Becker S, Niu Y, Yu C. Initial Clinical Experience of Stereotactic Radiotherapy of Breast Cancer Using GammaPod. Radiotherapy & Oncology, Volume 123, Supplement 1, p.S641, May 2017.
70. Molitoris J, Turkaj A, Trombetta L, Badiyan S, Bentzen S, Mishra M, Mehta M, Regine WF, Kaiser A. Mean Glucose during Chemoradiation for Glioblastoma is an Independent Predictor of Survival. Int. J. Radiation Oncology Biol Phys, Volume 99 (2), suppl, p.E95–E96, October 2017.
71. Snider J, Diwanji T, Regine WF, Langen K, Zhu M. A novel method for the delivery of 3-dimensional high-dose spatially fractionated radiotherapy with pencil beam scanning proton therapy: Maximizing the benefit of the Bragg peak. Int. J. Radiation Oncology Biol Phys, Volume 99 (2), suppl, p.S232–S233, October 2017.
72. Onyeuku N, Snider J, Regine WF, Simone C, Langen K, Diwanji T, Houser T, Le Q, Zhu M. Single- and Multi-CT Robust Optimization Improves Robustness to Anatomic Changes in Head and Neck Cancer Patients Treated with Intensity Modulated Proton Therapy. Int. J. Radiation Oncology Biol Phys, Volume 102 (3), suppl, p.e529–e530, November 2018.
BOOK CHAPTERS/TEXTBOOKS:
1. Regine WF. Postoperative Adjuvant Therapy for Pancreatic Cancer: Past, Present, and Future Trial Development. In: MD Anderson Solid Tumor Oncology Series: Pancreatic Cancer. Evans DB, Pisters PWT, Abbruzzese JL, eds. Spinger-Verlag, 2001;235-242.
2. Regine WF, Hanna N, DeSimone P, Cohen A. Rectal Cancer. In: Clinical Oncology, 3rd Edition Abeloff M, ed. Churchill Livingstone, 2003; 1943-1966.
3. Kwok Y, Garofalo MC, Regine WF. Postoperative Adjuvant Therapy and the Rationale for the US Intergroup Trial. In: “Van Hoff D, Evans D, Hruban, RH, eds. Jones and Bartlett, 2005;395-404.
4. Garofalo MC, Flannery T, Regine WF. The Case for Adjuvant Chemoradiation for Pancreatic Cancer. In: Best Practice & Research Clinical Gastroenterology, eds. Elsevier, Vol 20, No 2, pp. 403-416, 2006.
5. Patel S, Garofalo MC, Regine WF. Role of Radiotherapy in Treatment of Pancreatic Cancer. (Chapter 81) In: Rao B, Beger H, Neoptolemos J, Shiratori K, Lerch M, eds. The Pancreas: An Integrated Textbook of Basic Science, Medicine and Surgery, Blackwell Publishing, Ltd., April 2008.
6. Kwok Y, Patchell RA, Regine WF. Palliation of Brain and Spinal Cord Metastases. In: Principles & Practice of Radiation Oncology, 5th Edition, Lippincott, Williams and Wilkins Publishing. 2008;1974-1985.
7. Suh JH, Barnett GH, Regine WF. Stereotactic Radiosurgery for Brain Metastases. In: Chin LC, Regine WF eds. Principles & Practice of Stereotactic Radiosurgery. Springer Publishing. 2008; 181-191.
8. Patchell RA, Regine WF. Whole Brain Radiation Therapy for Brain Metastases. In: Chin LC, Regine WF, eds. Principles & Practice of Stereotactic Radiosurgery. Springer Publishing 2008; 201-206.
9. Chin LS, Regine WF, Editors. Principles and Practice of Stereotacic Radiosurgery, Springer Publishing, April, 2008.
10. Garofalo MC, Regine WF. Adjuvant Chemoradiation for Pancreatic Cancer: Past, Present, and Future. In: M.D. Anderson Solid Tumor Oncology Series. Pancreatic Cancer. Lowy, Leach, Philip, eds. 2008; 535-548.
11. Cohen AM, Garofalo MC, DeSimone PA, Hanna NN, Regine WF. Cancer of the Rectum. In: Clinical Oncology 4th Edition. Abeloff M, Armitage JO, Neiderhuber JE, Kastan MB, McKenna WG, eds. Churchill Livingstone, 2008; 1535-1556.
12. Pandya N, Garofalo MC, Regine WF. Adjuvant Chemoradiation Therapy for Pancreatic Cancer. In: Handbook of Pancreatic Cancer. Neoptolemos J, Urrutia R, Abbruzzese J, Büchler M, eds. Springer New York Publishing 2010; pp 1079-1092.
13. Kwok Y, Patchell RA, Regine WF. Management of Overt Central Nervous System Metastases: Brain and Spinal Cord. In: Principles and Practice of Lung Cancer, Fourth Edition. Pass, HI, Carbone DP, Johnson DH, Minna JD, Scagliotti GV, Turris III AT, eds. Lippincott Williams & Wilkins, 2010; 911-926.
14. Kwok Y, Patchell, Regine WF. Palliation of Brain and Spinal Cord Metastases. In: Perez and Brady’s Principles and Practice of Radiation Oncology, Sixth Edition. Edward C. Halperin, MD, David E. Wazer, MD, Carlos A. Perez, MD, and Luther W. Brady, MD. eds. Lippincott Williams & Wilkins, 2013; 1766-1777.
15. Herman JM, Regine WF, Shokek O, Gastrointestinal Pancreatic Cancer Section. In: Radiation Oncology Difficult Cases and Practical Management, eds. William Small, Jr, Tim R. Williams, Eric D. Donnelly, 2013; 43-51.
16. Mahmod U, Husain Z, Kwok Y, Regine WF. Stereotactic Radiosurgery (SRS) versus Whole Brain Radiation Therapy (WBRT) in the Management of Multiple Brain Metastases. In: Controversies in Neuro-Oncology, Best Evidence Medicine for Brain Tumor Surgery, Alfredo Quinones-Hinojosa, Shaan M. Raza, 2013; 244-251.
17. Yovino S, Kwok Y, Regine WF. Brain and Cranial Nerves. Chapter: ALERT • Adverse Late Effects of Cancer Treatment, Part of the series Medical Radiology, Volume 2: Normal Tissue Specific Sites and Systems. Springer-Verlag Berlin Heidelberg 2013; pp 1-20.
18. Chin LS, Regine WF. Editors. Principles and Practice of Stereotacic Radiosurgery, Second Edition, Springer Publishing, 2015.
19. Kaiser, A, Pandya N, Garofalo MC, Regine WF. Adjuvant Chemoradiation Therapy for Pancreatic Cancer. In: Handbook of Pancreatic Cancer, volume I by Neoptolemos J, Urrutia R, Abbruzzese J, Büchler M, eds. Springer New York Publishing 2010; pp 1080-1088 (updates submitted May, 2017).
20. Trifiletti D, Showalter TN and Mishra MV. Comparative effectiveness research for proton beam therapy. In: Boggs HD, Mahajan A, Regine WF, Mehta M, eds. Principles and Practice of Proton Therapy. Advanced Medical Publishing, Inc. 2017.
21. Narang M, Mohindra P, Mishra M, Regine WF, Kwok Y. Radiation oncology emergencies. Hematol Oncol Clin North Am. 2020 Feb;34(1) pp 279-292.
PATENTS/INVENTIONS:
2006 D’Souza W., Yu CX, Suntha M, Regine WF, McAvoy T. Techniques for Compensating Movement of a Treatment Target in a Patient
2008 Yu CX, Yu YS, Regine WF. Method and Equipment for Image-Guided Stereotactic Radiosurgery of Breast Cancer (Gammapod)
2018 Yu CX, Regine WF. Single-Arc Dose Painting for Precision Radiation Therapy
PRESENTATIONS:
NATIONAL (Research)
1. Murine Bone Marrow Macrophage Colony-Forming Unit Response to Radiation +40-420C: Potential Implications for Combined Total Body Irradiation and Hyperthermia. 33rd Annual Scientific Meeting of the American Society for therapeutic Radiology and Oncology, Washington, DC, November, 1991. [Poster].
2. Evaluation of Local Control with Selective Use of Low-Dose Irradiation Following Induction/Preoperative Chemotherapy for Locally AdvancedRhabdomyosarcoma. 35th Annual Scientific Meeting of the American Society for Therapeutic Radiology and Oncology, New Orleans, LA, October, 1993.
3. Use of Altered Radiation (RT) Dose and Fractionation in Patients with Unresectable Rhabdomyosarcoma (RMS) Based Upon Disease Status Following Induction Therapy:The St. Jude experience.34th Annual Meeting of the American Society of Clinical Oncology, Dallas, TX, May, 1994. [Poster]
4. Efficacy of Postoperative Irradiation for Recurrent Squamous Cell Carcinoma of the Head and Neck. 4th International Conference on Head and Neck Cancer, Toronto, Canada, July, 1996.
5. Dose-Intensive Chemoradiation Following Pancreaticoduodenectomy for Pancreatic Carcinoma – A Phase I Study. 38th Annual Scientific Meeting of the American Society of Radiology and Oncology, Los Angeles, CA, October, 1996.[Poster]
6. Results of Postoperative Irradiation for Squamous Cell Carcinoma of the Head and Neck: Is There a Difference Between Primary and Recurrent Disease? 39th Annual Scientific Meeting of the American Society of Radiology and Oncology, Orlando, FL, October, 1997. [Poster]
7. Results of High-Dose Intra-Arterial Cisplatin and Hyperfractionated Radiation Therapy in Patients with High Volume Unfavorable Squamous Cell Carcinoma of the Head and Neck. 34th Annual Meeting of the American Society of Clinical Oncology, Los Angeles, CA, May, 1998. [Poster]
8. A Randomized Prospective Trial of the Benefit of Postoperative Radiotherapy in the Treatment of Single Metastases to the Brain. 40th Annual Scientific Meeting of the American Society for Therapeutic Radiology and Oncology, Phoenix, AZ, October, 1998.
9. A Phase I Study of Fractionated Stereotactic Radiosurgery and Conventional External Beam Radiation Therapy for Unfavorable Intracranial Tumors. LINAC Radiosurgery – 1999 Meeting, Orlando, FL, December, 1999.
10. Combined Fractionated Gamma Knife Stereotactic Radiosurgery and Conventional Radiation Therapy for UnfavorableGliomas: A Phase I Study. 10th International Meeting of the Leksell Gamma Knife Society, Squaw Valley, CA, April, 2000.
11. High-Dose Intra-Arterial Cisplatin Boost with Hyperfractionated Radiation Therapy for Advanced Squamous Cell Carcinoma of the Head and Neck. 36th Annual Meeting of the American Society of Clinical Oncology, New Orleans, LA, May, 2000. [Poster Discussion]
12. Neurocognitive Outcome in Brain Metastasis Patients Treated with Accelerated Fractionation vs. Accelerated Hyperfractionation Whole Brain Radiotherapy: An Analysis from RTOG Study 91-04. 42nd Annual Scientific Meeting of the American Society for Therapeutic Radiology and Oncology, Boston, MA, October, 2000.
13. Gamma Knife Radiosurgery Alone following High Resolution MRI in Patients with Newly Diagnosed Brain Metastases: Results and Implications. 5th Annual Meeting of the Society for Neuro-Oncology, Chicago, IL, November, 2000.
14. A Phase II Study of concomitant Hyperfractionated Radiation Therapy and Double Dose Intra-Arterial Cisplatin for Squamous Cell Carcinoma of the Head and Neck. 37th Annual Meeting of the American Society of Clinical Oncology, San Francisco, CA, May, 2001. [Poster]
15. Risk of Symptomatic Brain Tumor Recurrence and Neurologic Deficit Following Gamma Knife Radiosurgery Alone for Single Metastases to the Brain. 14th International Conference On Brain Tumor Research and Therapy, Asheville, NC, May, 2001. [Poster]
16. Efficacy of 20 Gy Gamma Knife Stereotactic Radiosurgery With or Without Whole Brain Radiation Therapy for < 2 cm Brain Metastases. 5th International Stereotactic Radiosurgery Society Congress, Las Vegas, Nevada, June, 2001.
17. Prognostic Factors in Patients with Resected Single Brain Metastases: Evaluation of Recursive Partitioning Analysis Classes I and II. 43rd Annual Scientific Meeting of the American Society for Therapeutic Radiology and Oncology, San Francisco, CA, November, 2001.
18. Feasibility of Neurocognitive Outcome Evaluations in Patients with Brain Metastases in a MultiInstitutional Cooperative Group Setting: Results of Radiation Therapy Oncology Group (RTOG) Trial BR-0018. 44th Annual Scientific Meeting of the American Society for Therapeutic Radiology and Oncology, New Orleans, LA, October, 2002.
19. Metastatic spinal cord compression: A Randomized Trial of Direct Decompressive Surgical Resection plus Radiotherapy vs. Radiotherapy Alone. 45th Annual Scientific Meeting of the American Society for Therapeutic Radiology and Oncology, Salt Lake City, UT, October 2003.
20. Radiation Therapy as a Chemosensitizer of Gemcitabine in Patients with Metastatic/Unresectable Tumors of the Gastrointestinal Tract – a Phase I/II Study Exploring a New Treatment Paradigm. 47th Annual Scientific Meeting of the American Society for Therapeutic Radiology and Oncology, Denver, CO, October 2005.
21. A Phase III study of adjuvant pre and post chemoradiation 5-FU vs. gemcitabine for resected pancreatic adenocarcinoma. 42nd Annual Meeting of the American Society of Clinical Oncology, Atlanta, GA, June, 2006.
22. RTOG 9704: A Phase III Study of Adjuvant Pre and Post Chemoradiation 5-FU vs. Gemcitabine for Resected Pancreatic Adenocarcinoma. 48th Annual Scientific Meeting of the American Society of Therapeutic Radiology and Oncology, Philadelphia, PA, November, 2006.
23. Post-Resectional CA 19-9 Values ≥ 90 Are Associated with Significantly Worse Survival In Patients With Pancreatic Carcinoma Treated With Adjuvant Therapy on RTOG 9704 – Implications For Current And Future Trials. 49th Annual Scientific Meeting of the American Society of Therapeutic Radiology and Oncology, Los Angeles, PA, October, 2007.
24. 5-Year Results of the Phase III Intergroup Trial (RTOG 97-04) of Adjuvant Pre and Post Chemoradiation (CRT) 5-FU vs. Gemcitabine (G) for Resected Pancreatic Adenocarcinoma: Implications for Future International Design, 51st Annual Scientific Meeting of the American Society of Therapeutic Radiology and Oncology, Chicago, IL, November, 2009.
25. Postresection CA19-9 & Surgical Margin Status (SMS) Associations with Local-Regional (LRF) & Distant Failure (DF) in Pancreatic Patients (pts): NRG Oncology/RTOG 9704 Secondary Analysis. 2015 ASCO Gastrointestinal Oncology Symposium, San Francisco, CA, January, 2015. [Poster]
26. Prospective and Concurrent Analysis of Postresection CA19-9 Level and Surgical Margin Status (SMS) as Predictors of Pattern of Disease Recurrence Following Adjuvant Treatment for Pancreatic Carcinoma: NRG Oncology/RTOG Secondary Analysis. 57th Annual Scientific Meeing of the American Society of Therapeutic Radiology and Oncology, October, 2015.
27. Insurance Approval for Proton Therapy in Patients with Thoracic Malignancies: An Experience from a Cost-Neutral Payor Environment. National Proton Therapy Conference, virtual, April, 2021.
REGIONAL
1. The Combined Modality Treatment of Rectal Cancer. Section on Radiation Oncology, Philadelphia Roentgen Ray Society Meeting, Philadelphia, PA, January, 1992.
2. The Role of Radiation in the Treatment of Adenoid Cystic Carcinoma of the Palate. 22nd Annual Radiation Oncology Clinical Research Seminar, Gainesville, FL, April, 1992.
3. Pancreatic Cancer - Beyond Surgery is There a Role for Adjuvant Therapy? University of Kentucky/Department of Radiation Medicine Symposium: New Trends in the Management of G.I. Cancer, Lexington, KY, June, 1996.
4. New Combined Treatment Modalities for Advanced Cancer of the Head and Neck. University of Kentucky/Department of Radiation Medicine Symposium: New Trends in the Management of Head and Neck Cancer, Lexington, KY, September, 1996.
5. Use of Gamma Knife Radiosurgery in the Management and Treatment of Malignant Primary Brain Tumors. University of Kentucky Neurosciences Institute Symposium: New Trends in the Management of Central Nervous System Disease, Lexington, KY, February, 1997.
6. Gamma Radiosurgery for Trigeminal Neuralgia. Kentucky Neurosciences Institute Symposium: New Trends in the Management of Trigeminal Neuralgia, Lexington, KY, July, 1997.
7. Introducton to Gamma Knife Radiosurgery. The First Annual University of Kentucky Radiaton Therapy Conference, Lexington, KY, October, 1997.
8. Current Status of Adjunctive Therapy Trials in the Management of Resectable Pancreatic Cancer. University of Kentucky/Department of Radiation Medicine Symposium: New Trends in the Treatment of Upper G.I. Cancer, Lexington, KY, August, 1999.
9. High Dose Spatially Fractionated Radiation (GRID): A New Paradigm in the Management of Advanced Cancers. Second Annual Simon Kramer Institute Oncology Conference, New Philadephia, PA, August, 2002. [Poster].
10. Radiotherapy & Surgery/Radiosurgery in the Treatment of Brain Metastases. Greenebaum Cancer Center Hematology/Oncology Grand Rounds, Baltimore, MD, September, 2003.
11. “Introduction of the Gammapod System”, University of Maryland, Baltimore Foundation Board of Trustees, Baltimore MD, February, 2010.
12. Radiation Oncology – The Power of Partnership”, University of Maryland Medical System Board Retreat, St. Michael’s MD, October, 2010.
13. “Redefining the Paradigm for Cancer Care: The Future of the University of Maryland Department of Radiation Oncology at the UM Marlene and Stewart Greenebaum Cancer Center. University of Maryland School of Medicine Development Event, The Breakers Palm Beach, FL, February, 2012.
14. “The Power of Partnerships, Passion and People! – Much to be Proud of and a Glimpse into the Future”, University of Maryland School of Medicine Board of Visitors Spring Meeting, Baltimore, MD, April, 2013.
15. “University of Maryland Radiation Oncology: The Power of Partnerships, Passion and People! A 10-Year Review and a Glimpse into the Future:, University of Maryland Greenebaum Cancer Center, Board of Visitors, Baltimore MD, May, 2013.
16. “University of Maryland Radiation Oncology: Cutting Edge Clinical Care and Protons – Benefiting the State of Maryland and Beyond! State of Maryland House Appropriations Committee, Baltimore, MD 2013.
17. “University of Maryland Radiation Oncology: Cutting Edge Clinical Care and Protons – Benefiting the State of Maryland and Beyond! Prospective Hotel Developers for University of Maryland BioPark, Baltimore, MD, August, 2013.
18. “Proton Therapy Arrives to the Mid-Atlantic: What does it mean to you and your patients”, Invited speaker. University of Maryland – Midtown Grand Rounds, Baltimore, MD. July, 2015.
19. “Proton Therapy Arrives to the Mid-Atlantic: What does it mean to you and your patients”, Invited speaker. University of Maryland – Charles Regional Grand Rounds, LaPlata, MD. August, 2015.
20. “Proton Therapy Arrives to the Mid-Atlantic: What does it mean to you and your patients”, Invited speaker. Saint Agnes Hospital, Baltimore, MD. September, 2015.
21. “Proton Therapy Arrives to the Mid-Atlantic: What does it mean to you and your patients”, Invited speaker. Holy Cross Hospital - Grand Rounds, Silver Springs, MD. January, 2016.
22. “Proton Therapy Arrives to the Mid-Atlantic: What does it mean to you and your patients”, Invited speaker. Prince George's Hospital Center – Grand Rounds, Cheverly, MD. February, 2016.
23. “Proton Therapy Arrives to the Mid-Atlantic: What does it mean to you and your patients”, Invited speaker. Mercy Medical Center– Grand Rounds, Baltimore, MD. March, 2016.
24. “Proton Therapy Arrives to the Mid-Atlantic: What does it mean to you and your patients”, Invited speaker - Eastern Shore regional Health System Cancer Program Leadership, Easton, MD. June, 2016.
25. “Proton Therapy Arrives to the Mid-Atlantic: What does it mean to you and your patients”, Invited speaker – Peninsula Regional Medical Center Tumor Board, Salisbury, MD. April, 2017.
26. “Proton Therapy Arrives to the Mid-Atlantic: What does it mean to you and your patients”, Invited speaker – Medical Society of the District of Columbia (MSDC), June, 2017.
27. “Proton Therapy Arrives to the Mid-Atlantic: What does it mean to you and your patients”, Invited speaker – Kaiser Permanente, Woodlawn Medical Center, Baltimore, MD, July, 2017.
28. “Proton Therapy Arrives to the Mid-Atlantic: What does it mean to you and your patients”, Invited speaker – Kaiser Permanente, Tysons Corner Medical Center, McLean, VA, August, 2017.
29. “Proton Therapy Arrives to the Mid-Atlantic: What does it mean to you and your patients”, Invited speaker – ENTAA Care Practice, Glen Burnie, MD, August, 2017.
30. “Bringing Innovation and New Hope to Head and Neck Cancer Patients”, Invited speaker – Eastern Shore ENT & Allergy Associates, PA., Salisbury, MD, August, 2017.
31. “Proton Therapy Arrives to the Mid-Atlantic: What does it mean to you and your patients”, Invited WebEx speaker – Kaiser Permanente, Baltimore – Washington, MD, September 2017.
32. “Proton Therapy Arrives to the Mid-Atlantic: What does it mean to you and your GI Cancer patients”, Invited speaker – Digestive Disorder Associates, Annapolis, MD, September 2017.
33. “Proton Therapy Arrives to the Mid-Atlantic: What does it mean to you and your GI Cancer patients”, Invited speaker – Capital Digestive Care, Chevy Chase, MD, November 2017.
34. “Proton Therapy Arrives to the Mid-Atlantic: What does it mean to you and your patients”, Invited speaker – Atlantic General Hospital, Berlin, MD, November 2017.
35. “Bringing Innovation and New Hope to GI Cancer Patients”, Invited speaker – St. Joseph’s Medical Canter GI Multidisciplinary Tumor Conference, Towson, MD, September 2019.
36. “Protons and Beyond: Emerging Technologies in Cancer Therapy”, Invited speaker – Maryland/ DC Society of Clinical Oncology, virtual, July 2020.
VISITING PROFESSORSHIPS AND INVITED PRESENTATIONS:
1. All Rectal Cancers Are Not Alike - Optimizing the Use ofAdjuvant Therapy. “Visiting Professor” at the Department of Radiation Oncology,University of Maryland, Baltimore, MD, July 1997.
2. Trimodality Therapy for Malignancies of the Gastrointestinal Tract: The Evolving Roles of Surgery, Chemotherapy and Radiation. “Invited Speaker” at St. Vincent’s Medical Center, Jacksonville, FL, January 1998.
3. Adjuvant Therapy for Pancreatic Cancer: Current Status. “Invited Speaker” at Gulf Coast Medical Center, Panama City,FL, January 1999.
4. What is the Role of Radiotherapy in the Management of Colorectal Cancer? “Invited Speaker” at 4th Annual National VA Oncology Symposium, Washington DC, October 1999.
5. What are the Roles of Adjuvant Therapy in Pancreatic Cancer and Radiation Therapy in the Management of Colorectal Cancer: Current Status. “Invited Speaker” at Centre Community Hospital, State College, PA, February 2000.
6. Preoperative Chemoradiation in Fixed (T4) Distal Rectal Cancer: Dose Time Factors for Pathologic Complete Response. “Invited Speaker” at American College of Surgeons, Kentucky Chapter, Spring Meeting, Lexington, KY, March, 2000.
7. Is Whole Brain Radiation Therapy a Standard of Care Following resection of a Single Brain Metastases? Yes. “Invited Speaker & Panelist” for Panel Presentation – ‘Controversies in the Management of Brain Metastases’ at 42th Annual Scientific Meeting of the American Society for Therapeutic Radiology and Oncology, Boston, MA, October 2000
8. The Radiation Oncologist’s Perspective on Stereotactic Radiosurgery. “Invited Speaker” at International Conference on Technology in Cancer Research and Treatment in the New Millennium, Albany, NY, June 2001.
9. CNS Criteria Development for the common Toxicity Criteria. “Invited Speaker & Panelist” for ‘Validation Studies and Criteria Development Process’ at NCI Sponsored Late Effects Workshop, St. Petersburg Beach, FL, April, 2002.
10. Something Old, Something New, and Something Blue: Evolving Paradigms from the University of Kentucky Head & Neck & GI Cancer Programs. “Invited Speaker” at Gulf Coast Medical Center, Panama City, FL, July 2002.
11. Use of Low–Dose Radiation as a Chemosensitizer for H&N Carcinomas–A New Treatment Paradigm. “Invited Speaker” at Sixth Annual International Conference & Workshop-New and Future Developments in Radiotherapy. Las Vegas, NV, August, 2002.
12. Locally Advanced Squamous Cell Carcinoma of the Head and Neck: Old and New Treatment Paradigms – The Joseph Marconis, MD Memorial Lecture. “Invited Speaker” at Second Annual Simon Kramer Institute Oncology Conference. New Philadephia, PA, August 2002.
13. Radiotherapy and Surgery/Radiosurgery in the Treatment of Brian Metastases. “Invited Speaker” at Current Approaches To The Treatment Of Brain Metastases Symposium, CME Symposium in conjunction with 44th Annual Scientific Meeting of the American Society for Therapeutic Radiology and Oncology, New Orleans, LA, October 2002.
14. Current Management of Low-grade Gliomas. “Invited Speaker” at Exploring Advances in the Management of Gliomas Symposium. CME Symposium in conjunction with 45th Annual Scientic Meeting of the American Society for Therapeutic Radiology and Oncology, Salt Lake City, UT, October 2003.
15. Adjuvant Multimodality Treatment with Gemcitabine vs. 5-FU in Pancreatic Cancer: Status of U.S. Intergroup Trial. “Invited Speaker” at Chemotherapy Foundation Symposium XXI. Innovative Cancer Therapy for Tommorrow. New York City, NY, November 2003.
16. Metastatic spinal cord compression: A randomized trial of directo decompressive surgical resection plus radiotherapy vs. radiotherapy alone. “Invited Speaker” at Radiological Society of North American Scientific Assembly and Annual Meeting Program. Chicago, IL, December 2003.
17. Quality of Life in Brain Neoplasms. “Invited Speaker” at Neuro-Oncology 2004 – Current Concepts Meeting, Cleveland Clinic Education Foundation. Orlando, FL, February 2004.
18. “Pancreatic Cancer: Status of Adjuvant Multimodality U.S. Intergroup Phase III Trial” and “Metastatic Epidural Spinal Cord Compression (MESCC): Clinical Update”. “Visiting Professor” at the Department of Radiation Oncology, University of Pennsylvania, Philadelphia, Pennsylvania, September 2004.
19. Neurologic sequelae of Brain Metastases: Recognition and Impact on Therapeutic Approach. “Invited Speaker” at WBRT for the Management of Brain Metastases: Novel Approaches to Improve the Therapeutic Index, CME Syposium in conjunction with 46th Annual Scientific Meeting of the American Society for Therapeutic Radiology and Oncology. Atlanta Georgia, October 2004.
20. Management of GI Tumors-ASTRO 2004 Review. “Invited Speaker” at The Cleveland Clinic Callahan Center for Radiation Oncology 6th Annual ASTRO Review 2004. Cleveland, OH, November 2004.
21. Pancreatic Cancer: Review of Adjuvant Multimodality Trials and Status of U.S. Intergroup Phase III Trial. “Visiting Professor” at The Department of Radiation Oncology, Cleveland Clinic, Cleveland, OH, November 2004.
22. Malignant Gliomas: ‘Impacting Survival with New Treatment Strategies’ and ‘State-of-the-Art Treatment Approaches for Brain Metastases’ – “Invited Speaker” at Central Baptist Hospital, Cancer Center, Lexington Kentucky, February 2005
23. ‘State-of-the-Art Treatment Approaches for Brain Metastases’ – “Invited Speaker” at Southern Illinois Cancer Center, Marion, Illinois, February 2005.
24. ‘State-of-the-Art Treatment Approaches for Brain Metastases’ – “Invited Speaker” at Norris Cancer Center at USC, Los Angeles, CA, March 2005.
25. ‘Use of Gamma Knife Radiosurgery for Brain Tumors’ – “Invited Speaker” at Baltimore Oncology Club Annual Meeting, Sheraton Baltimore North, Towson, MD, March 2005.
26. ‘State-of-the-Art Treatment Approaches for Brain Metastases’ – “Invited Speaker” at Akron City Hospital, Akron City, OH, March 2005.
27. ‘State-of-the-Art Treatment Approaches for Brain Metastases’ – “Invited Speaker” at Houston Northwest Cancer program, Houston, TX, April 2005.
28. ‘State-of-the-Art Treatment Approaches for Brain Metastases’ – “Invited Speaker” at Sinai Hospital Cancer Institute, Baltimore, MD May 2005.
29. ‘State-of-the-Art Treatment Approaches for Brain Metastases’ – “Invited Speaker” at Tate Cancer Center, Glen Burnie, MD, May 2005.
30. ‘State-of-the-Art Treatment Approaches for Brain Metastases’ – “Invited Speaker” at Pluta Cancer Center, Rochester, NY, May 2005. ‘Resolved: Currently available Adjuvant Therapies of Pancreatic Cancer are effective – Agree’ (Debate) “Invited Speaker” at International Society of Gastrointestinal Oncology – The 2005 Gastrointestinal Oncology Conference, Arlington, VA, July 2005.
31. ‘Pancreatic Cancer – Adjuvant Postoperative Chemoradiation’ - “Invited Speaker” at 12th International Gastrointestinal Cancer Conference, Charlottesville, VA, October 2005.
32. ‘Glioblastoma Multiforme (& AA): The Multidisciplinary Approach to Treatment’ - “Invited Speaker” for Christiana Medical Center at The Hilton, Wilmington, DE, October 2005.
33. ‘Glioblastoma Multiforme (&AA): The Multidisciplinary Approach to Treatment’ – “Invited Speaker” for University of Kentucky, Markey Cancer Center, Lexington, KY, December 2005.
34. ‘Brain Metastases: Truths and Misconceptions’: “Visiting Professor” at the Department of Radiation Oncology and Molecular Radiation Sciences, The Johns Hopkins University, Baltimore, MD, April 2006.
35. ‘Management of Brain Metastases’: Radiosurgery, Whole Brain Radiation Therapy and Quality of Life. “Invited Speaker” Washington Hospital Center, Washington, DC, May 2006.
36. ‘Management of Metatatic Brain Tumors - A Case Study “Invited Speaker” Sixth Annual Simon Kramer Institute Oncologic Symposium, New Philadelphia, PA, May 2006.
37. ‘Management of Brain Metastases: Concepts and Controversies’ “Invited Speaker” University of New Mexico Cancer Research and Treatment Center, Albuquerque, NM, June, 2006.
38. ‘Should Whole Brain Radiation Therapy follow Focal Therapy of a Single and Multiple Brain Metastases? “Invited Speaker” at Educational Session, 42nd Annual Meeting of the American Society of Clinical Oncology, Atlanta, GA, June, 2006.
39. ‘Management of Brain Metastases: Concepts and Controversies’ “Visiting Professor” at University of Colorado, Anschutz Cancer Pavillion, Aurora, CO, June, 2006.
40. ‘Pancreatic Cancer – Adjuvant Postoperative Chemoradiation: Where We Have Been and Where We Are Going; “Invited Speaker” at Southern Illinois Cancer Center, Marion, Illinois, June, 2006.
41. ‘Management of Brain Metastases: Concepts and Controversies’ “Visiting Professor” at University of Virginia, Charlottesville, VA, June, 2006.
42. ‘Management of Brain Metastases: Concepts and Controversies’ “Visiting Professor” at Oregon Health and Science University, Department of Radiation Oncology, Portland OR, July, 2006.
43. ‘Management of Brain Metastases: Concepts and Controversies’ – “Invited Speaker” at Central Baptist Hospital, Cancer Center, Lexington KY, July, 2006.
44. ‘Management of Brain Metastases: Concepts and Controversies’ – “Invited Speaker” for University of Kentucky, Markey Cancer Center, Lexington, KY, July, 2006.
45. ‘The Role of Gemcitabine in the Adjuvant Treatment of Pancreatic Cancer’ and ‘Management of Brain Metastases: Concepts and Controversies’ – “Visiting Professor” at Norris Cancer Center and Department of Radiation Oncology as USC, Los Angeles, CA, August, 2006.
46. ‘Brain Metastases: Facts and Fiction’ – “Recrutiment Seminar” at The M.D. Anderson Cancer Center, Houston, TX, September, 2006.
47. ‘Management of Brain Metastases: Concepts and Controversies’ at Rocky Mountain Cancer Center, Casper Wyoming, September, 2006.
48. ‘Adjuvant Therapy for Pancreatic Cancer “Invited Speaker” at International Society of Gastrointestinal Oncology – The 2006 Gastrointestinal Oncology Conference, Arlington, VA, September, 2006.
49. ‘Management of Brain Metastases: Concepts and Controversies’ at Bay Medical Regional Cancer Center, Panama City, FL, October, 2006.
50. ‘Surgery, Radiosurgery, or Whole Brain Radiation Therapy for Brain Metastases: When & Why’ – “Visiting Professor” at Hahneman University, Department of Radiation Oncology, Philadelphia, PA, October, 2006.
51. ‘Management of Brain Metastases: Concepts and Controversies’ at St. Mary’s Medical Center, Huntington, West VA, October, 2006.
52. ‘Management of Brain Metastases: Concepts and Controversies’ at York Cancer Center, York, PA, October, 2006.
53. Low-Grade Gliomas, “Invited Speaker” at Management of Gliomas: A Case Based Approach, CME Symposium in conjunction with Annual Scientific Meeting of the American Society for Therapeutic Radiology and Oncology, Philadelphia, PA, November, 2006.
54. ‘Management of Brain Metastases: Concepts and Controversies’ at Mt. Nittany Medical Center, College Park, PA, December, 2006.
55. ‘Glioblastoma Multiforme: The Multidisciplinary Approach to Treatment; and ‘Management of Brain Metastases: Concepts & Controversies’ “Visiting Professor” at the University of Florida/Shands Cancer Center and Department of Radiation Oncology, Gainesville, FL, December, 2006.
56. ‘Contemporary Management of Brain Metastases: ‘The Patricia Hunt Reynolds Memorial Lecture’ “Invited Speaker” at the Reading Hospital and Medical Center, Grand Rounds, West Reading, PA, April, 2007.
57. ‘Adjuvant Management of Pancreatic Carcinoma’ – “Visiting Professor”, Department of Radiation Oncology Grand Rounds, Henry Ford Health System, Detroit, Michigan, May, 2007.
58. ‘Malignant Gliomas, Hope & Life: Using Biology to Refine Treatment’ Grand Rounds and “Visiting Professor” at the University of Kentucky, Department of Radiation Medicine, Hematology Oncology and Neurosurgery, Lexington, KY, July, 2007.
59. ‘Malignant Gliomas, Hope & Life: Using Biology to Refine Treatment’ Grand Rounds and “Visiting Professor” at Vanderbilt University, Department of Radiation Oncology, Nashville, TN, August, 2007.
60. ‘Malignant Gliomas, Hope & Life: Using Biology to Refine Treatment’ Grand Rounds and “Visiting Professor” at the UPMC Cancer Center, Radiation Oncology Department, Philadelphia, PA, August, 2007.
61. ‘Malignant Gliomas, Hope & Life: Using Biology to Refine Treatment’ Grand Rounds and “Visiting Professor” at the Valley Hospital, Paramus, NJ, September, 2007.
62. ‘Malignant Gliomas, Hope & Life: Using Biology to Refine Treatment’ “Invited Speaker” at the Community Medical Center, Toms River, NJ, September, 2007.
63. ‘Malignant Gliomas, Hope & Life: Using Biology to Refine Treatment’ “Visiting Professor” and “Invited Speaker” at Virginia Commonwealth University, Massey Cancer Center, Richmond, VA, September, 2007.
64. ‘Malignant Gliomas, Hope & Life: Using Biology to Refine Treatment’ Grand Rounds and “Visiting Professor” at Rocky Mountain Cancer Center, Casper Wyoming, November, 2007.
65. ‘Malignant Gliomas, Hope & Life: Using Biology to Refine Treatment’ Grand Rounds and “Invited Speaker” at Prince William Hospital, Manassas, Virginia, November, 2007.
66. ‘Combined Modality Treatment’ “Panel Discussant” – AHPBA Sponsored Consensus Conference on Resectable and Borderline Resectable Pancreas Cancer, Orlando, Fl, January, 2008.
67. ‘Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract – Multidisciplinary Treatment’ “Moderator” – General Session –, Science and Multidisciplinary Management of GI Malignancies 2008 American Society of Clinical Oncology Gastrointestinal Cancers Symposium, Orlando, FL, January, 2008.
68. ‘Pancreatic Cancer: Review and Current Status of Postoperative Adjuvant Multimodality Therapy’ “Invited Speaker” at Philadelphia Roentgen Ray Society Meeting, Philadelphia, PA, May 2008.
69. ‘Cases in Glioblastoma Multiforme: The Multidisciplinary Approach’. “Invited Speaker” Scherin Plough Oncology, Baltimore, MD, May 2008.
70. ‘Cases in Glioblastoma Multiforme: The Multidisciplinary Approach’. “Invited Speaker” Schering Plough Oncology, University of Mississippi, Jackson, MS, June 2008.
71. ‘Cases in Glioblastoma Multiforme: The Multidisciplinary Approach’. “Invited Speaker” Schering Plough Oncology, Emory University, Atlanta, GA, June, 2008.
72. ‘Brain Metastases Management: Facts & Fallacies’ “Invited Speaker” FDA White Oak Seminar Series, Silver Spring, MD, August, 2008.
73. ‘The Impact of Whole Brain Radiation Therapy After Focal Therapy: Facts, and Fiction’. “Invited Speaker” Seventh Annual International Neuro Oncology Updates, The Johns Hopkins Comprehensive Brain Tumor Center. Baltimore, MD September, 2008.
74. ‘Stereotactic Radiosurgery for Brain Metastases: Alone or with Whole Brain Radiation Therapy’. “Invited Speaker” Second Annual Lecture Series, Advances in Stereotactic Radiosurgery, Boston University School f Medicine, Boston, MA, September, 2008.
75. ‘Novel Radiation Approaches in the Treatment of Pancreas Cancer’. “Invited Speaker” Fourth Annual Oncology Congress, San Francisco, CA, September, 2008.
76. ‘Adjuvant Postoperative Chemoradiotherapy for Pancreatic Cancer: Results of the U.S. Intergroup Study’. “Invited Speaker” The 15th International Gastrointestinal Oncology Conference, Arcachon, France, October, 2008.
77. ‘Pancreatic Carcinoma – Adjuvant Postoperative Chemoradiation: Past, Present and Future’. “Visiting Professor” UMDNJ-Robert Wood Johnson Medical School and The Cancer Institute of New Jersey, New Brunswick, NJ, January, 2009.
78. ‘Cancers of the Colon and Rectum: “Prevention, Screening, and Diagnosis’ Chairman of General Session American Society of Clinical Oncology 2009 Gastrointestinal Cancers Symposium, Science and Multidisciplinary Management of GI Malignancies San Francisco, CA, January 2009.
79. ‘Surgery, Radiosurgery and/or Whole Brain Radiotherapy for Brain Metastases: When, Why and How? “Keynote Speaker” 39th Annual University of Florida Radiation Oncology Outcomes Tracking Seminar, University of Florida College of Medicine, February, 2009.
80. ‘Pancreatic Carcinoma – Adjuvant Postoperative Chemoradiation: Where Have We Come and Where Are We Going? “Keynote Speaker” 39th Annual University of Florida Radiation Oncology Outcomes Tracking Seminar, University of Florida College of Medicine, February, 2009.
81. ‘Use of Gamma Knife Radiosurgery for Primary, Metastatic and Benign Brain Tumors: “Invited Speaker, South Carolina Oncology Society Conference – American Community Cancer Centers, Charleston, SC, August, 2009.
82. “Surgery, Radiosurgery and/or Whole Brain Radiotherapy: Concepts and Controversies”. “Visiting Professor” United States National Cancer Institute – Radiation Oncology Branch, Bethesda, MD, September, 2009.
83. “Brain Metastases Management” Invited Speaker & Visiting Professor, University of Arizona Cancer Center and Department of Radiation Oncology, Tucson, AZ, January, 2010.
84. ‘Cancers of the Pancreas, Small Bowel and Hepatobiliary Tract: Multidisciplinary Mangement, Chairman of General Session, American Society of Clinical Oncology 2010 Gastrointestinal Cancers Symposium, Science and Multidisciplinary Management of GI Malignancies Orlando, FL January, 2010.
85. “Pancreatic Carcinoma and Brain Metastases – Adjuvant Postoperative Therapy: Review and Rationale”, Invited Speaker and Visiting Professor, The Kaiser Permanente Radiation Oncology Department, Los Angeles CA, January, 2012.
86. “Pancreatic Carcinoma – Adjuvant Postoperative Chemoradiation: Review and Current Status”, 2) “The Role of RT in Combined Modality Therapy for Esophageal Cancer”, 3) “Best of ASTRO 2011 Gastrointestinal”. Invited Speaker, Los Angeles Radiological Socient 64th Annual Midwinter Conference, Pasadena, CA, January, 2012.
87. “Evolving Status of Postoperative Adjuvant Chemoradiation for Pancreatic Cancer” “Invited Speaker and “Visiting Professor” United States National Cancer Institute – Radiation Oncology Branch, Bethesda, MD, March, 2012.
88. “Brain Metastases Management” “Invited Speaker and Visiting Professor”, Department of Radiation Oncology, State University of New York, Syracuse, NY, May, 2012.
89. “Brain Metastases: Truth and Consequences”, Invited Speaker, Perelman Cancer Center, University of Pennsylvania, Philadelphia, PA, January, 2013.
90. “The Gammapod System: A Paradigm Change in the Treatment of Early Stage Breast Cancer”, Visiting Professor, Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA, January, 2013.
91. “How to Make An Offsite Program Successful”, Invited Speaker, 2013 Society of Chairs of Academic Radiation Oncology Programs (SCAROP), Washington, DC, April, 2013.
92. “Adjuvant Therapy for Pancreatic Cancer: Past, Present and Future”, Visiting Professor, Department of Radiation Oncology and Cancer Center at the University of Kansas, Kansas City, MO, September, 2013.
93. “Phase III Radiotherapy Trials: Lessons Learned and Moving Forward”, Invited Speaker, 2nd Annual Course on Clinical Trials in Radiation Oncology, University of Pennsylvania, Philadelphia, PA, October, 2013.
94. “Brain Metastases: Clinical Management and Trial(s) Critique”, “Visiting Professor Lecture Series”, Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan, February, 2014.
95. “The Management of Gastrointestinal Cancers – 2014 Update”, “Visiting Professor Lecture Series”, Walter Reed National Military Medical Center, Bethesda, MD, April, 2014.
96. ” Management of Brain Metastases”, Visiting Professor, Department of Radiation Oncology, University of Nebraska, Omaha, NE, June, 2014.
97. “Adjuvant Therapy for Pancreatic Cancer: Where we have been and where we are going?”, Invited speaker, Fred and Pamela BUFFETT Cancer Center, University of Nebraska, Omaha, NE, June, 2014.
98. “Adjuvant Therapy for Pancreatic Cancer: Then, Now and Into the Future”, “Visiting Professor Lecture Series”, Department of Radiation Oncology, University of Virginia, Charlottesville, VA November 2014.
99. “The GammaPod: The First SBRT System Dedicated to the Treatment of Breast Cancer”, “Visiting Professor Lecture Series”, Department of Radiation Oncology, Grand Rounds, Weill-Cornell Medical College, New York, NY, February 2015.
100. “Proton Radiotherapy Trials: From Registry to Randomization and the Associated Challenges”, “Keynote Speaker”, Clinical Trials in Radiation Oncology: Course and Workshop, University of Pennsylvania, Philadelphia, PA, April 2015.
101. “3-D Conformal Radiotherapy is the Standard of Care in the Neoadjuvant Treatment of Rectal Cancer and Avenues to Reduce Toxicity with Radioprotectors Should be Priortized (A Debate)”, Invited Speaker, 25th Annual Meeting of the American College of Radiation Oncology (ACRO), Crystal City, Washington, DC, May, 2015.
102. “Need for cost effectiveness in radiotherapy”, Invited Panelist, Varian Medical Systems American Association of Physicists in Medicine Users Meeting, Anaheim, CA, July 2015.
103. “NRG and Randomized Proton-Photon Clinical Trials”, Keynote Speaker, Proton Therapy Center 2nd National Education Conference, MD Anderson Cancer Center, Houston, TX, September 2015.
104. “Healthcare Provider’s Perspective: Value of Proton Therapy as the Treatment for Cancer Diagnoses – Safe, Effective, Cost-Effective, Reference/Discount Pricing” Invited Speaker and Panelist, Proton Therapy Center 2nd National Education Conference, MD Anderson Cancer Center, Houston, TX, September 2015.
105. “Proton Radiotherapy Clinical Trials: Challenges and Hope for the Future”, “Visiting Professor Lecture Series”, Department of Radiation Oncology, Medstar Georgetown University Hospital, Washington, DC, Februaty 2016.
106. “Proton Therapy Coverage - National Health Provider Perspective. The value of Proton Therapy as a treatment for Cancer Diagnoses” , Invted Speaker, Proton Advisory Board Meeting – West Region – Scripps Proton Therapy, San Diego, CA, March 2016.
107. “The Maryland Proton Treatment Center Model for Engagement of Regional Providers and Payers”, Keynote Speaker, Varian Medical Systems ‘Linking Minds’ Users meeting at the ASTRO 2016 Annual Meeting, Boston, MA, September 2016.
108. “Realizing the Promise and Potential of Proton Therapy”, Invited Speaker, Varian Medical Systems Investors Meeting at the ASTRO 2016 Annual Meeting, Boston, MA, September 2016.
109. “The Evolving Role of Adjuvant Radiotherapy for Gastric Adenocarcinoma”, Invited Speaker, Symposium on Hepatic Oncology at Whistler, Whistler, BC, Canada, February 2017.
110. “The Maryland Proton Treatment Center (MPTC): Making the Benefits of Proton Therapy Available as Regional Healthcare Resource”, Invited Speaker and Visiting Professor, University of Cincinnati, Department of Radiation Oncology, Cincinnati, OH, February, 2017.
111. “Proton Therapy – An Aproach Towards More Effective Engagement of Payors”, Invited Speaker, National Proton Conference, Orlando, FL, March, 2017.
112. “The Maryland Proton Treatment Center (MPTC): A Regional Healthcare Resource Partnering with Providers and Payor”, Invited Speaker, Grand Rounds, M.D. Anderson Departmemt of Radiation Oncology, Houston, TX, August 2017.
113. “The Maryland Proton Treatment Center (MPTC): A Regional Healthcare Resource Increasing Patient Access to Clinical Trials and Proton Therapy”, Invited Speaker and Visiting Professor, Rutgers Cancer Institute of New Jersey, Department of Radiation Oncology, New Brunswick, NJ, September 2017.
114. “The Maryland Proton Treatment Center (MPTC): A Regional Healthcare Resource” Invited Speaker, Varian, Gemelli Institute, Rome, at 59th Annual Scientific Meeting of the American Society of Therapeutic Radiology and Oncology, San Diego, CA September, 2017.
115. “Making Proton Therapy a ‘Regional Healthcare Resource’ Benefiting Patients, Providers and Payors”, Invited Speaker, Miami Cancer Institute, Baptist Health South Florida, Miami, FL, October 2017.
116. “The Maryland Proton Treatment Center: A Regional Healthcare Resource Model”, Invited Speaker, American College of Radiation Oncology (ACRO) Proton Therapy Symposium, Baltimore, MD, December 2017.
117. “Clinical Clinical Experiences using High-Dose Spatial Fractionation - What are the results? How are they measured and judged as “success”? What is comparison?”. Discussant at the Workshop on Understanding High-Dose, Ultra-Dose-Rate and Spatial Fractionated Radiotherapy Workshop, National Cancer Institute, Bethesda, MD, August 2018.
118. “Making Proton Therapy a ‘Regional Healthcare Resource’ Benefiting Patients, Providers and Payors”, Invited Speaker and Visiting Professor, Northwell Health, Department of Radiation Medicine, Center for Advanced Medicine, Long Island, NY, December 2018.
119. “Post-resection CA19-9 and Margin Status as Predictors of Recurrence after Adjuvant Treatment of Pancreatic Carcinoma: Analysis of NRG Oncology RTOG Trial 9704”, Invited Speaker, NRG Oncology Scientific Session, NRG Oncology Semi-annual Meeting, Phoenix, AZ, February 2019.
120. “Proton Therapy for Gastrointestinal Cancers” and “Making Proton Therapy Accessible as a Regional Healthcare Resource: Overcoming Challenges and Increasing Clinical Trial Accrual”, Invited Speaker and Visiting Professor (virtual), University of Miami, Department of Radiation Oncology, June 2020.
121. “The Future of Proton Therapy and Innovation”, Invited Speaker and Panelist, UCSF Radiation Oncology Update: Predicting Benefit from Advanced Radiation Technologies (virtual), University of California San Francisco, April 2021.
WORKS-IN-PROGRESS:
1. Kaiser A, Simone C, McMath G, Chiaramonte D, Berman B, Regine WF. Integrative Proton Therapy: A Novel, Personalized Strategy Combining Precision Proton Treatment with Integrative Medicine Modalities to Improve Quality of Life and Outcomes for Cancer Patients. (Submitted for 2018 Integrative Medicine International Congress in Baltimore, October 2017).
2. Dye N, Kaiser A, Zhu M, Regine WF; Simone C, Badiyan S. Hypofractionated Pencil Beam Scanning Proton Beam Therapy for Liver Tumors. (Submitted for 2018 ASTRO meeting, February 2018).
3. Remick J, Kowalski E, Clevenger M, Snider JW, Regine WF, Vujaskovic Z. The Impact of Hyperthermia Therapy on Patient Referrals and Patterns of Care within a Radiation Oncology Department. (Submitted to Hyperthermia Conference, March 2018).
4. Neil M, Langen K, Snider J, Regine WF, Eley J, Zhu M. A Script for Automated PBS Proton GRID Plan Creation. (Accepted for the 2018 AAPM Annual Meeting for the General Poster Discussion Session, April 2018).
5. Rhee J, Kubiczek E, Regine WF, Yu C. A mouse model for studying spatially fractionated radiotherapy. (Accepted to NCI GRID Symposium, August 2018).
6. Zandberg D, Diwanji T, Morales R, Tyer T, Snider J, Engelman A, Bentzen S, Galloway T, Malyapa R, Saeidi N, Keiss A, Lubek J, Ord R, Dyalram D, Hatten K, Wolf J, Taylor R, Papadimitriou J, Mehra R, Quon H, Ridge D, Bauman J, Regine WF, Suntha M, Strome S, Cullen K. A Phase II trial of reirradiation (ReRT) plus Pembrolizumab for locoregional inoperable recurrence or second primary squamous cell carcinoma of the head and neck (SCCHN): Analysis of early toxicity. (Submitted to Society for Immunotherapy of Cancer (SITC) 2018, August 2018).
7. Sood A, Bivona L, Mahkzoumi Z, Hausner P, Miller P, Regine WF , Snider J, Ng V. Beyond the dermis: A case series of high-risk invasive squamous cell carcinoma. (Submitted to Journal of Surgical Oncology, November 2018).
8. DeCesaris C, Choi J, Regine WF, Burrows W, Carr S, Simone III C, Molitoris J. Pathologic complete response (pCR) rates and outcomes after neoadjuvant chemoradiotherapy with proton or photon radiation for distal esophageal adenocarcinoma. (Submitted to the 2019 Particle Therapy Cooperative Group (PTCOG) Conference, January 2019).
9. Koroulakis A, Molitoris J, Kaiser A, Hanna N, Jiang Y, Regine WF. Early Results of Re-irradiation for Rectal Cancer Using Pencil-Beam Scanning Proton Therapy Are Promising. (Submitted to the 2019 Particle Therapy Cooperative Group (PTCOG) Conference, January 2019).
10. DeCesaris C, McCarrol R, Regine WF, Simone C, Choi I, Molitoris J. Assessing Outcomes of Patients Treated with Thoracoabdominal Re-irradiation Utilizing Proton Pencil-Beam Scanning for Primary or Recurrent Malignancies of the Esophagus and Gastroesophageal Junction. (Submitted for 2019 ASTRO, February 2019).
11. Koroulakis A, Molitoris J, Kaiser A, Hanna N, Jiang Y, Regine WF. Re-irradiation for Rectal Cancer: A Single Institution Experience Utilizing Photons and Protons. (Submitted for 2019 ASTRO, February 2019).
12. Ng V, Sausville E, Miller K, Suzuki I, Snider J, Regine WF, Kallen M, Ioffe O, Mulligan M, Davis D, Carr S, Hausner P, Davila E, Ciavattone N, Cao X. Neoadjuvant Combination Immunotherapy / Radiation for High-Risk Soft Tissue Sarcoma (NEXIS): Preliminary Results from an Integrated Phase I/II, Single-Arm, Prospective Clinical Trial. (Submitted for 2019 Musculoskeletal Tumor Society (MSTS) 2019 Annual Meeting, April 2019).
13. Tracey B, Bregman J, Regine WF, Rolfo C, Schocket L. Intravitreal Bevacizumab for recurrent choroidal metastasis following radiation therapy. (Submitted to Retina Brief Cases & Reports, June 2019).
14. Tracey B, Bregman J, Regine WF, Rolfo C, Schocket L. Intravitreal Bevacizumab for recurrent choroidal metastasis following radiation therapy. (Submitted to OSLI Retina, August 2019).
15. Remick J, Kowalski E, Khairnar R, Sun K, Morse E, Cherng H, Poirier Y, Lamichhane N, Becker SJ, Chen S, Patel A, Kwok Y, Nichols E, Mohindra P, Woodworth G, Regine WF, Mishra M. A Comparison of Single-Fraction versus Multiple-Fraction Stereotactic Radiosurgery in the Treatment of Brain Metastases: A Multicenter Analysis. (Submitted to Journal of Neurosurgery,October 2019).
16. Griffin R, Ahmed M, Amendola B, Belyakov O, Bentzen S, Butterworth K, Chang S, Coleman C, Djonov V, Formenti S, Glatstein E, Guha C, Kalnicki S, Le Q, Loo B, Mahadevan A, Massaccesi M, Maxim P, Mohiuddin Ma, Mohiuddin Mo, Mayr N, Obcemea C, Petersson K, Regine WF, Roach M, Romanelli P, Simone C, Snider J, Spitz D, Vikram B, Vozenin M, Abdel-Wahab M, Welsh J, Wu X, Limoli C. Understanding High-Dose, Ultra-High Dose-Rate and Spatially Fractionated Radiotherapy. (Submitted to IJROBP, December 2019).
17. Alexander G, Remick J, Kowalski E, Sun K, Poirier Y, Stewart J, Lamichhane N, Eisenberg H, Slawson R, Woodworth G, Regine WF, Mishra M. GammaKnife versus Linac-based Stereotactic Radiosurgery for the Treatment of Brain Metastases: Clinical Outcomes and Toxicity Analysis. (Submitted for 2020 ASTRO, February 2020).
18. Bryant J, Hartsell W, Tsai H, Regine WF, Laramore G, Chang J, Stevens C, Vargas C, Chuong M. Proton beam therapy for abdominopelvic reirradiation: Outcomes from the Proton Collaborative Group REG001-09 Trial. (Submitted for 2020 ASTRO, February 2020).
19. Koroulakis A, Sullivan M, Molitoris J, Hausner P, Jiang Y, Miller R, Regine WF. The Effect of Radiation Therapy on Malignant Fistulae of Anorectal Cancers. (Submitted for 2020 ASTRO, February 2020).
20. Rao A, Sun K, Zhu M, Mossahebi S, Houser T, Jatczak J, Zakhary M, Regine WF, Miller R, Bentzen S, Mishra M. The Effects of Maximum Monitor Unit Thresholds on Pencil Beam Scanning Proton Therapy Plan Quality for Treatment of Central Nervous System and Skull Base Tumors. (Submitted to IJROBP, April 2020).
21. Kowalski E, Remick J, Khairnar R, Sun K, Morse E, Cherng H, Poirier Y, Lamichhane N, Chen S, Becker S, Molitoris J, Regine WF, Kwok Y, Mishra M. Checkpoint Inhibition in Patients Treated with Stereotactic Radiation for Brain Metastases. (Submitted to PRO, April 2020).
22. Koroulakis A, Molitoris J, Kaiser A, Hanna N, Bafford A, Jiang Y, Bentzen S, Regine WF. Re-Irradiation for Rectal Cancer Using Pencil-Beam Scanning Proton Therapy: A Single Institutional Experience. (Submitted to Radiotherapy and Oncology, May 2020).
23. Koroulakis A, Molitoris J, Kaiser A, Hanna N, Bafford A, Jiang Y, Bentzen S, Regine WF. Proton Re-irradiation for Rectal Cancer: A Single Institutional Experience. (Submitted to Cancer, June 2020).
24. Goodman, Regine WF, WF et. Al “QA review of NRG/RTOG 0848”. (Submitted to NRG Oncology, December 2020).
25. Ben-Josef E, Winter K, Williams T, Regine WF, DiPetrillo T, Leasure N, Mowat R, Kim H, Koenig J, Narayan S, Bush D, Fromm M, Guha C. β-catenin is independently associated with outcome in pancreatic cancer: An analysis of NRG Oncology/RTOG 9704. (Submitted for 2021 ASTRO, February 2021).
26. Williams T, Moughan J, Ben-Josef E, Regine WF , Timmers C, Rob R, DiPetrillo T, Leasure N, Mowat R, Kim H, Koenig J, Narayan S, Bush D, Fromm M, Guha C. High SMAD4 Expression is Associated with Better Clinical Outcomes in Patients with Resectable Pancreatic Cancer: An analysis of NRG Oncology/RTOG 9704. . (Submitted for 2021 ASTRO, February 2021).
27. Tchelebi L, Winter K, Abrams R, Safran H, Regine WF, McNulty S, Wu A, Du K, Seaward S,Bian S, Aljumaily R, Shivnani A, Moore T, Crocenzi T, DiPetrillo T, Kuykendal A, Crane C,Goodman K. Analysis of Radiation Therapy Quality Assurance in NRG Oncology RTOG 0848. (Submitted for 2021 ASTRO, February 2021).
28. Morris L, Viehman J, Baclay J, Chang D, Kerans S, Regine WF, Johung K, Jethwa K, Neibart S, Jabbour S, Hallemeier C. SBRT for the Treatment of Isolated Local Recurrence of Resected Pancreatic Cancer. (Submitted for 2021 ASTRO, February 2021).
29. Zhu M, Patel P, Bradley J, McDonald M, Chen H, Snider J, Regine WF, Langen K. Proton GRID and Lattice therapy using pencil beam scanning with breath-hold. (Submitted for PTCOG, February 2021).
30. Alexander G, Savla B, Berg L, Sun K, Remick J, Kowalski E, Chen S, Lamichhane N, Regine WF, Mishra M. PD-L1 Expression Level of Primary Tumor as a Predictor of Local Control and Symptomatic Radiation Necrosis in Patients with Brain Metastases Undergoing SRS/fSRT With Concurrent Immunotherapy. (Submitted for 2021 ASTRO, February 2021).
31. Savla B, Alexander G, Sun K, Bentzen S, Mossahebi S, Kwok Y, Regine WF, Mishra M. Incidence of symptomatic brain injury following pencil beam scanning proton beam therapy for management of central nervous system tumors. (Submitted for 2021 ASTRO, February 2021).
32. Berger M, DeCesaris C, Burrows W, Greenwald B, Tyer T, Glass E, Mishra M, Suntha M, Regine WF, Molitoris J. Nodal Clearance as a Predictor of Oncologic Outcomes in Esophageal and Gastroesophageal Junction Malignancies Receiving Trimodality Therapy. (Submitted for 2021 ASTRO, February 2021).
33. Mohindra P, Scull A, Molitoris J, Mishra M, Patel A, Witek M, Regine WF. Insurance Approval for Proton Therapy in Patients with Thoracic Malignancies: An Experience from a Cost-Neutral Payor Environment. (Submitted for 2021 ASTRO, February 2021).
34. Zhu M, Langen K, Chen H, Snider J, Regine WF, Patel P, Bradley J, McDonald M, Pouya S. Dosimetric investigation of inverse-optimized Proton GRID and Lattice treatment plans with a clinical pencil beam scanning system. (Submitted for 2021 AAPM annual meeting, February 2021).
35. Kunaprayoon D, Sun K, Mundis M, Mossahebi S, Houser T, S. Bentzen S, Vujaskovicz Z , Regine WF. Dosimetric parameters associated with pathologic response in patients undergoing preoperative spatially fractionated radiotherapy (GRID) for soft tissue sarcoma. (Submitted for 2021 ASTRO, February 2021).
36. Alexander G, Remick J, Kowalski E, Sun K, Poirier Y, Becker S, Lamichhane N, Eisenberg H, Slawson R, Woodworth G, Regine WF, Mishra M. Gamma-Knife versus Linac-based Stereotactic Radiosurgery for the Treatment of Brain Metastases: Clinical Outcomes and Toxicity Analysis. (Submitted for 2021 American Radium Society (ARS) meeting, April 2021).
37. Williams T, Moughan J, Ben-Josef E, Regine WF, Timmers C, Robb R, DiPetrillo T, Leasure N, Mowat R, Kim H, Koenig J, Narayan S, Bush D, Fromm M, Guha C. High SMAD4 Expression is Associated with Better Clinical Outcomes in Patients with Resectable Pancreatic Cancer: An analysis of NRG Oncology/RTOG 9704. (Accepted abstract for 2021 ASTRO, May 2021).
38. Morris L, Viehman J, Baclay R, Chang D, Kerans S, Molitoris J, Regine WF, Johung K, Jethwa K, Neibart S, Jabbou S, Hallemeier C. SBRT for the Treatment of Isolated Local Recurrence of Resected Pancreatic Cancer. (Accepted abstract for 2021 ASTRO, May 2021).
INVESTIGATIONAL STUDIES/ GRANT SUPPORT
INSTITUTIONAL:
1. Phase I study of combined fractionated stereotactic radiosurgery and conventional external beam irradiation in the treatment of intracranial tumors [ Principal Investigator ] – Unfunded – 1994 – 2003.
2. Paclitaxel, carboplatin and radiotherapy as induction therapy in advanced head and neck cancer [Co–Investigator ] –$Funded Study – 9/00-4/02 - $90,000 (Total)
3. An open label phase I study of TNF-alpha gene therapy with radiation therapy for locally advanced, recurrent, or metastatic solid tumors [ Co-Investigator ] - $Funded Study – 10/00-10/01 - $180,349 (Total).
4. An open-label, dose-esclation study of TNFeradeTM biologic with radiation therapy as an adjunct to surgery or for palliation in soft tissue sarcoma of the extremities [ Co-Investigator ] $Funded Study - 1/02-12/03 - $93,210 ( Total).
5. The effect of cancer on the cancer patient caregiver [ Co-Investigator ] – $Funded Pilot Study ( ACS – 10K ) – 2001-2002.
6. Phase I/II evaluation of radiation and gemcitabine in locally advanced or metastatic tumors of the gastrointestinal tract [ Principal Investigator ] – $Funded Study – 7/99-12/00 - $48,010 (Total): $38,111(Direct) + $9,899 (Indirect) – sponsor – Eli Lilly
7. A multinational, multicenter, double-blind, placebo-controlled, randomized, phase III clinical trial to determine the efficacy and safety of IB-367 rinse in reducing the severity of oral mucositis in patients receiving radiotherapy for head and neck malignancy [ Institutional Principal Investigator ] - $Funded Study – 9/00-6/02 - $136,895 (Total): $107,360 (Direct) + $29,535 (Indirect) – Sponsor – Pharmanet Inc.
8. Radiation Therapy Oncology Group Studies [ Institutional – Full Member – Principal Investigator ] - $Funded Study – 8/96-12/02 - $284,433 (Total): $247,638 (Direct) + $36,795 (Indirect) – Sponsor – American College of Radiology.
9. A Phase I Study of Low-Dose Upper Abdominal Radiation Therapy (UART) or Whole (W) ART as a Chemosensitizer in Patients with Locally Advanced or Metastatic Tumors of the Gastrointestinal Tract or Ovary [ Prinicipal Investigator ] - $ Funded Study – 11/00-11/02 - $19,700 (Total): $15,641 (Direct) = $4,059 (Indirect) – Sponsor – Eli Lilly.
10. Families and Cancer: Stress, Resources, and Outcomes [ Co-Investigator ] - $Funded Pilot Study ((Institutional – 15K ) – 2002-2003.
11. Cancer caregiving and the stress process. Submitted May 2002 for RFA for funding ( 100 K ) by Small Grants Program for Behavioral Research in Cancer Control [ Co-Investigator ]
12. Compreshensive support for Breast Cancer Caregivers. Submitted Jun 2002 for funding ( 425K ) by US Department of Defense [ Co-Investigator ]
13. A Phase I/II Study of Low-Dose Upper Abdominal Radiation Therapy (UART) or Whole (W) ART as a Chemosensitizer in Patients with Locally Advanced or Metastatic Tumors of the Gastrointestinal Tract or Ovary [ Prinicipal Investigator ] - $ Funded Study – 10/03-03/06 - $213,000 (Total): $170,800 (Direct) = $42,700.00 (Indirect) – Sponsor – Eli Lilly.
14. Master Research Agreement – Varian Medical Systems. $Funded study – 4/05 – 4/10 - $1.25M (Total) [Co-Investigate]
15. “Hand-held humidification device for prevention and treatment of chemoradiotherapy-induced mucositis”. 2015 Awarded a UM Ventures Seed Grant of $10,000.
NATIONAL
1. A phase III postoperative adjuvant protocol for pancreatic adenocarcinoma. Intergroup/RTOG protocol #97-04 [ Principal Investigator/Study Chairman ] – Activated 7/98; closed 7/02.
2. A feasibility study of neurocognitive evaluation in patients treated for brain metastases. RTOG Protocol #BR-0018 [ Principal Investigator/Study Chairman ] – Activated 11/00; closed 8/01
3. A Phase II trial of conventional radiation therapy followed by intratumoral bleomycin delivered using a refillable, sustained release device (IND# 46,592) for the treatment of supratentorial glioblastoma. RTOG Protocol #BR-0013 [ Study Co-Chairman ] – Activated 6/01; closed 6/04
4. A Phase III Trial Evaluating Both Erlotinib and Chemoradiation as Adjuvant Treatment for Patients with Resected Head of Pancreas Adenocarcinoma. RTOG Protocol #0848 [Study Co-Chairman] Activated 11/09
TEACHING/ EDUCATION AND MENTORING EXPERIENCE:
INSTITUTIONAL
Medical Student Education - Monthly lecture to senior students in radiology elective; Section of Radiation Oncology, University of Tennessee, Memphis, Tennessee 1992 – 1994
Medical Student Education – Preceptor for students rotating through department, 1994 – present (~ 2/ year)
University Hospital Tumor Board - Biannual presentation/lecture in clinical radiation oncology, 1992 – 2001
Radiation Oncology Resident Education
a) Annual lectures in clinical radiation oncology, 1994 – present ( ~ 8 students)
b) Annual lecture in radiation biology, 1996, 1998, 1999
c) Morning quality assurance/teaching conference ( 3-5 X’s/week ), 1994 – present ( ~ 12 students)
d) Monthly journal club, 1994 – present ( ~ 8 students)
e) Quarterly morbidity and mortality conference, 1994 – present ( ~ 8 students)
f) Oral Mock Boards (quarterly), 1997 – present ( ~ 4 students)
Radiation Therapy Student Education - Annual lectures in clinical radiation oncology, 1994 – 2002 (~ 6 students)
Medical Physics Student Education - Annual lectures in clinical radiation oncology, 1994 – 2001(~ 6 students)
Hematology – Oncology Fellow Education – Preceptor for fellows rotating through department, 1994 – 2002
( 1/ year) and annual lectures (2006)
Neurosurgery Resident Education - Grand Rounds/Annual lecture in clinical radiation oncology, 1995 – 2002
( ~ 10 students)
Gamma Knife Radiosurgery/Neuro-Oncology Conference - Weekly, 1996 – present
Neuroradiology Conference - Weekly, 1994 – 2002
E.N.T. Resident Education - Annual lecture in clinical radiation oncology, 1995 – 2002 ( ~ 6 students)
Multidisciplinary Head and Neck Cancer Conference - Weekly, 1994 – 2002 ( ~ 10 students)
Multidisciplinary Gastrointestinal Conference - Weekly, 1996 – present ( ~ 10 students)
Ophthalmology Resident Education - Lecture in clinical radiation oncology, 1995
Radiation Therapist Education - Lecturer in University of Kentucky Radiation Therapist Seminar Series, 1997
Neurology Resident Education - Grand Rounds - lecture in clinical radiation oncology, 1997
Surgery Resident Education - Head and Neck Working Group and Head and Neck Skills Course Co-Instructer in developing and implementation ofstructured clinical instruction module for head and neck cancer - Radiation Therapy Section, 1997
Dental Residents – Lecture in use of Gamma Knife for Trigeminal Neuralgia – 2000
St. Claire Oral Examiner for Institutional Medical Physics Masters Degree Program - 1996 – 2002
Sponsor of Resident Research – Mihoko Fugita, MD, PhD – Second Malignant Neoplasia in Patients with T1 Glottic Cancer Treated with Radiation (Manuscript Published) – 1997
Sponsor of Resident Research – Gregory H. Carlsen, MD – Use of Spatially Fractionated (GRID) Radiation as a Novel Means of Dose Escalation in the Treatment of Large Volume Carcinomas Involving Head and Neck Sites (Paper Published) -1998-1999
Sponsor of Medical Student Research – Eugene S. Gamburg, MS III – The Prognostic Significance of Midline Shift on Survival of Patients Presenting with Glioblastoma Multiforme (Presented at National Meeting and Manuscript Published) – 1998-1999
Sponsor of Resident Research – Jennifer Huhn, DO – Gamma Knife Radiosurgery Alone Following High Resolution MRI in Patients with Newly Diagnosed Brain Metastases: Results and Implications (Presented at National meeting and Manuscript Published) – 1999
Sponsor of Resident Research - Anil Dhople, MD – Gamma Knife Radiosurgery for Atypical Trigeminal Neuralgia (Presented at National Meeting and Paper, Published) – 2005
Sponsor of Resident Research - Todd Flannery, MD – The Impact of Definitive Thoracic Management in Patients with Single Brain Metastasis Treated with Raidosurgery (Presented at National Meeting paper published) – 2003
Sponsor of Medical Student Research – T. Brady Reid, MS II – Safety and Efficacy of Utilizing 20Gy Target Dose Gamma Knife Radiosurgery for Metastatic Brain Tumors with a Maxiumum Volume of 5 cc (Presented as Finalist at 2001 University of Kentucky Alpha Omega Alpha Student Research Day – paper published) – 2000-2001
Sponsor of Visiting Physician Research – Anna Rogosinska, MD – Prognostic Factors in Patients with Resected Single Brain Metastases: Evaluation of Recursive Partitioning Analysis (RPA) Classes I and II (Presented at National meeting and paper published) – 2001 – 2002
Sponsor of Medical Student Research – Michael Shehata, MS III – Gamma Knife Radiosurgery for Metastatic Brain Tumors with a Maximum Volume of 5 cc - The University of Kentucky Experience – (Presented at National meeting and paper published) - 2001-2003.
Sponsor of Medical Student Research - Alice Cheuk, MS IV – Imaging Correlates of Gamma Knife Outcome in Trigeminal Neuralgia (Paper published) – 2003-2004.
Sponsor of Medical Student Research - Pinaki Dutta, MS IV – Results of Repeat Gamma Knife Radiosurgery
for Retractory or Recurrent Trigeminal Neuralgia (Presented ASTRO 2004) – 2003-2004
Sponsor of Medical Student Research - Jerry Jaboin, MS IV – An Analysis of Dose-Staged Stereotactic Radiosurgery for Large Cerebral Arteriovenous Malformations (Presented ASTRO 2005) – 2004-2005
Sponsor of Resident Research - Shilpen Patel, MD – Evaluating the Influence of Dose-Rate on Outocme with Gamma Knife Stereotactic Radiosurgery in the Treatment of Trigeminal Neuralgia (Presented ASTRO 2005) – 2004-2005.
Sponsor of Medical Student Research - Josh R. Adams, MS IV - Long Term Follow-up of Gamma Knife Stereotactic Radiosurgery for Trigeminal Neuralgia (Presented ASTRO 2007, Paper Published) – 2006-2007
Sponsor of Resident Research - Susannah Yovino, MD – IMRT Decreases Acute GI Toxicity Among Patients Receiving Concurrent Chemoradiation for Upper Abdominal Malignancies (Presented at ASTRO 2008, paper published 2007-2013) and “Optimizing Brain Control in One-Year Survivors of Brain Metastases: A Single Institution Experience (Accepted for Publication in Journal of Radiation Oncology, 2013).
Sponsor of Resident Research – Geoffrey Neuner, MD – High-Dose Spatially fractionated GRID Radiation Therapy (SFGRT): A Comparison of Outcomes of Treatment Delivered Through Cerrobend GRID versus MLC Grid. (Presented at ASTRO 2008) – 2007-2008.
Sponsor of Resident Research – Elizabeth Nichols, MD – Post-Lumpectomy Target Colume Versus the Use of Pre-Lumpectomy Tumor Volume for Early Stage Breast Cancer: Implications for the Future. (Presented at ASTRO and the National Breast Meeting and published 2008-2009).
Sponsor of Resident Research – Elizabeth Nichols, MD - Factors Impacting White Matter Changes Following Whole Brain Radiation Therapy: (Submitted for 2010 ASTRO) 2009-2010.
Sponsor of Medical Student Research – Bert Maidment, MSIV – Analysis of Local Control in Patients Receiving IMRT for Resected Pancreas Cancer (Presented at ASTRO, 2010) – 2009-2010.
Sponsor of Resident Research – James W. Snider, MD - Use of “virtual” high dose rate (HDR) brachytherapy via spatially fractionated GRID radiation therapy (SFGRT) as part of neoadjuvant therapy in poor prognosis,bulky sarcomas. IJROBP 2014; 90(1): S767.(Presented at ASTRO Annual Meeting, 2014).
Sponsor of Resident Research – James W. Snider, MD -. A dosimetric comparison of a novel breast stereotactic radiotherapy (BSRT) device for the delivery of partial breast irradiation (PBI) versus intensity modulate dradiotherapy (IMRT) PBI. IJROBP 2014; 90(1): S17. (Presented at ASTRO Annual Meeting, 2014).
Sponsor of Resident Research – James W.Snider, MD - Theoretical improvements in cosmetic outcomes utilizing a novel breast stereotactic radiotherapy (BSRT) device compared to 3-dimensional partial breast irradiation using IMRT (IMRT PBI): a dosimetric analysis. IJROBP 2014;90(1): S278-279. (Presented at ASTRO Annual Meeting, 2014)
Sponsor of Resident Research – Jolinta Lin, MD Cancer Screening Patterns In Caregivers Accompanying Patients to Radiation Oncology. (Submitted for 2015 ASCO Annual Meeting).
Sponsor of Medical Student Research – Emily Shea Kowalski, 4th year Medical Student - Acute toxicities from neoadjuvant compared to adjuvant chemoradiation with the use of intensity modulated radiotherapy in resected pancreatic cancer patients. (Accepted at 57th ASTRO Annual Meeting) – 2014-2015.
Sponsor of Resident Research – Tony Koroulakis, MD, Proton Re-Irradiation of Rectal Cancer – 2019 – 2020.
E.N.T. Resident Education – Preceptor for residents rotating through department, 2002.
Nurse Practitioner Student Medical Dosimetrist Student Education – Annual lectures in clinical radiation oncology, ( ~ 2 students), 2003.
Course Director – “New Trends in the Management of Trigeminal Neuralgia”, University of Maryland Medical
System – CME – 2003 – 2005.
Education – Lecture on Head & Neck Cancer (~ 10 students), 2003.
“Gamma Radiosurgery for Trigeminal Neuralgia”, University of Maryland Medical System CME: Current Management of Trigeminal Neuralgia, Greater Baltimore Medical Center Hospital, Trigeminal Neuralogic Support Group Baltimore, MD, December, 2003.
“Gamma Radiosurgery for Trigeminal Neuralgia”, University of Maryland Medical System CME: Current Management of Trigeminal Neuralgia, Bethesda, MD, January 2004.
“Gamma Radiosurgery for Trigeminal Neuralgia”, Unversity of Maryland Medical System CME: Current Management of Trigeminal Neuraligia, Annapolis, MD, March 2004.
“Gamma Radiosurgery for Trigeminal Neuralgia”, and “Surgical Management for Trigeminal Neuralgia” University of Maryland Medical System CME: Current Management of Trigeminal Neuraligia, Cambridge, MD, October 2004.
“Surgical Management for Trigeminal Neuralgia”, University of Maryland Medical System CME: Current Management of Trigeminal Neuralgia, Holy Cross Hospital, Silver Spring, MD, November 2004.
“Gamma Radiosurgery for Trigeminal Neuralgia”, University of Maryland Medical System CME: Current Management of Trigeminal Neuralgia, Holy Cross Hospital, Silver Spring, MD, November 2004.
“Gamma Radiosurgery for Trigeminal Neuralgia”, University of Maryland Medical System CME: Current Management of Trigeminal Neuralgia, Valley Dental Society meeting, Pikesville, MD January 2005.
“State-of-the-Art Treatment Approaches for Brain Metastases” – “Invited Speaker” at Marlene and Stewart Greenebaum Cancer Center, Baltimore, MD, March, 2005.
“Malignant Gliomas: Impacting survival with New Treatment Strategies: - “Invited Speaker” – at Marlene and Stewart Greenebaum Cancer Center, April, 2005.
“Use of Gamma Knife Radiosurgery for Brain Tumors”, - “Invited Speaker” at Marlene and Stewart Greenebaum Cancer Center, January, 2006.
Course Director – “Radiation Oncology Symposium”(formerly known as “ASTRO Review”), University of Maryland School of Medicine – CME – 2005 to present.
Panel Discussant – “The Changing Approach to High-Grade Glioma Treatment”, CME Symposium in Conjunction with the American Association of Neurological Surgeons Annual Meeting, San Francisco, CA, April 2006.
“Adjuvant Postoperative Chemoradiation for Pancreatic Cancer: Where We Have Been and Where Are We Going” - Invited Speaker Hematology/Oncology Grand Rounds, University of Maryland Marlene and Stewart Greenebaum Cancer Center, Baltimore, MD, January, 2007.
“Moderator Pancreatic Session” The First Annual Gastrointestinal Cancer Symposium, University of Maryland Medical Center, Baltimore, MD, April 2009.
“Current Trends in The Treatment of Glioblastoma Multiforme” Moderator, Baltimore MD, April 2009.
“Stereotactic Radiosurgery, Surgery and/or Whole Brain Radiotherapy for Brain Metastases: When, How and Why?” CME Grand Rounds, Providence Hospital, Washington DC, September, 2009.
“Treatment for Brain Metastases When, How and Why”: Visiting Professor, Holy Cross Hospital, Silver Spring, Maryland, September 2009.
“Pancreatic Carcinoma – Adjuvant Postoperative Chemoradiation: Review and Current Status” – “Invited Speaker, University of Maryland GI Grand Rounds, January 2010.
“Moderator Innovations in Radiation-Based Diagnostics & Therapeutics for GI Malignancies” The Second Annual Gastrointestinal Cancer Symposium, University of Maryland Medical Center, Baltimore, MD, April 2010.
“Pancreatic Carcinoma – Adjuvant Postoperative Chemoradiation: Review and Current Starus” – Invited Speaker.
University of Maryland Marlene & Stewart Greenebaum Cancer Center, Physician Outreach CME, July 2011.
“Best of ASTRO 2011 – Gastrointestinal” – CME – 7th Annual Mid-Atlantic ASTRO Review, Baltimore, MD, January, 2012.
“Best of ASTRO 2011 and Evolving Radiation Techniques – Gastrointestinal” – Invited Speaker, University of Maryland GI Grand Rounds, February, 2012.
“The Gammapod System: A Paradigm Change in the Treatment of Early Stage Breast Cancer and an Opportunity for Multidisciplinary Collaboration: - Invited Speaker, University of Maryland Diagnostic Radiology and Nuclear Medicine Grand Rounds, December, 2012.
“Update on Pancreas Cancer – Advances in Radiation Therapy”, Invited Speaker, 8th Annual University of Maryland St. Joseph’s Medical Center Cancer Institute Symposium, November 2014.
Sponsor of Resident Research – Jill Remick, MD - The Downstream “Halo” Effect of a Proton Therapy Center on an Academic Medical Center. (Presented at ASTRO Annual Meeting, 2018; submitted IJROBP, 2019).
Sponsor of Resident Research – Anthony Koroulakis, MD - Re-irradiation for Rectal Cancer: A Single Institution Experience Utilizing Photons and Protons. (Submitted for 2019 ASTRO, February 2019).
“The Evolving Role of Radiation Therapy for Pancreatic Cancer”, Lecture (16 trainees), June, 2019.
“The Management of Rectal Cancer”, Lecture (16 trainees), Jan, 2021.
NATIONAL/INTERNATIONAL
American Board of Radiology Examiner in Radiation Oncology – Oral Exam GI, H&N & CNS/Peds -1998 – 2015
American Board of Radiology Examiner in Radiation Oncology – Written Exam – 2000 – 2007
Radiation Therapy Oncology Group New Invesitgators Committee (G.I. Cancer) – 2004 – 2007
“Meet the Professor Luncheon” at 46th Annual Scientific Meeting of the American Society for Therapeutic Radiology and Oncology – 2004
“Meet the Professor Luncheon” at 48th Annual Scientific Meeting of the American Society for Therapeutic Radiology and Oncology – 2006
Metastatic Brain Tumor – Concepts and Controversies: A Roundtable Discussion – Mehta MP, Gilbert MR, Lassman AB, Regine WF, Stieber VW. CME/CE accredited Grand Rounds program on Metastatic brain cancer, 2006.
The Gastrointestinal Cancers Symposium, (Sponsored by ASCO, ASTRO & SSO) Program Committee – Member 2007 – 2010.
The Gastrointestinal Cancers Symposium - Cancers of the Pancreas, Small Bowel and Hepatobiliary Tract Subcommittee member – 2007 – 2010.
American Board of Radiology Examiner in Radiation Oncology – Oral Exam Chairman – GI – 2007 – 2015
“Meet the Professor Luncheon” at 51st Annual Scientific Meeting of the American Society for Therapeutic Radiology and Oncology – 2009
ARRO Poster Walk, 51st, Annual Scientific Meeting of the American Society for Therapeutic Radiology and Oncology, 2009.
“Meet the Professor Luncheon” at 52nd Annual Scientific Meeting of the American Society for Therapeutic Radiology and Oncology, 2010.
ARRO Poster Walk, 52nd Annual Scientific Meeting of the American Society for Therapeutic Radiology and Oncology, 2010.
The Gastrointestinal Cancers Symposium, (Sponsored by ASCO, ASTRO & SSO) Program Committee – Member 2012 – 2013.
The Gastrointestinal Cancers Symposium, (Sponsored by ASCO, ASTRO & SSO) News Planning Team Member, 2012 – present.
The Gastrointestinal Cancers Symposium, Oral Abstract Session – Cancers of the Colon and Rectum, Chair and Moderator, San Francisco, CA, 2013.
“Management of Gastrointestinal Cancers”, ASTRO Spring Refresher Course, Chicago, IL 2013.
The Gastrointestinal Cancers Symposium, Oral Abstract Session – Cancers of the Pancreas, Small Bowel and Hepatobiliary Tract, Moderator, San Francisco, CA, 2014.
2014 – present Member, American Council for Graduate Medical Education (ACGME) Residency Review Committee (RRC) for Radiation Oncology.
Particle Therapy Cooperative Group – North America (PTCOG - NA) – Challenging cases session – Moderator, Houston, TX, 2014.
The Gastrointestinal Cancers Symposium, Oral Abstract Session – Cancers of the Pancreas, Small Bowel and Hepatobiliary Tract - Moderator, San Francisco, CA, 2015.
Particle Therapy Cooperative Group 54th (PTCOG 54th) Meeting – “Debate: Liver – Carbon vs. DS Protons vs. IMPT vs. SBRT vs. Y-90”. Session Co-Chair, San Diego, CA, 2015
Symposium on Hepatic Oncology at Whistler – Case Discussion – Hepatocellular Carcinoma – Panelist, Whistler, BC, Canada, 2017.
National Proton Conference 2017 – “Strategies for Engaging Health Insurance on Proton Therapy Coverage, Session Co-Moderator, Orlando, FL, March, 2017.
Particle Therapy Cooperative Group – North America (PTCOG - NA), 4th Annual Conference – “Original Contributions; Head/Neck + GI” – Moderator, Chicago, IL, October 2017.
Peer reviewer for “Radiation Therapy for Pancreatic Cancer: An ASTRO Evidence – Based Guideline”, 2018.
The Radiosurgery Society (RSS) Annual Scientific Meeting – “SRS vs. whole Brain Radiation Therapy for Brain Metastases – Is SRS a Slam Dunk for Brain Metastases?” – Advancing Value Based Care through Radiosurgery – Moderator, San Diego, CA, March 2019.
The Surgical Society of Oncology (SSO) Virtual Colorectal Cancer (CRC) Tumor Board – Radiation Oncology Panelist, May 2020.
REVIEW / EDITORIAL POSITIONS:
1994 - present Reviewer, International Journal of Radiation Oncology-Biology-Physics
1994 - present Reviewer, Cancer
1996 - present Reviewer, Journal of Clinical Oncology
1998 - present Reviewer, Journal of Neuro-Oncology
2001 - present Reviewer, Critical Reviews in Oncology/Hematology
2001 - 2002 Reviewer, Head & Neck
2002 - present Reviewer, Annals of Surgical Oncology
2001 - 2015 Board of Editors, Technology, Research and Cancer Treatment
2003 - 2006 Board of Editors, American Journal of Clinical Oncology
2007 - present Reviewer, Nature Clinical Practice Gastroenterology & Hepatology
2008 - present Board of Editors, Journal of Clinical Oncology
2010 - present Reviewer, Annals of Oncology
2010 - present Board of Editors, Journal of Gastrointestinal Oncology in Cancer Research and Treatment
2015 – present Board of Editors, ASTRO’s new Open Access Journal, Advances in Radiation Oncology
2016 – present Advisory Board Member, Keep Punching Foundation (Brain Tumor Foundation)
2019 – present Reviewer, British Journal of Radiology (BJR)
ADMINISTRATIVE EXPERIENCE / POSITIONS:
INSTITUTIONAL
1992 - 1994 Coordinator of Departmental Medical Student Rotations, Section of Radiation Oncology, University of Tennessee, Memphis, Tennessee
1994 Acting Clinical Chief, Section of Radiation Oncology, University of Tennessee, Memphis Tennessee
1994 - 2002 Coordinator of Departmental Hematology-Oncology Fellow Rotations
1994 - 2002 Departmental Clinical Research Coordinator
1994 - 1995 Member of Departmental Quality Assurance Committee
1995 - 1998 Member of Institutional Gastrointestinal Oncology Clinic Planning Committee
1996 - 1998 Member of Institutional Scientific Advisory Committee
1996 - 1998 Member of Institutional Gamma Knife Radiosurgery Business Planning Committee
1996 - 1998 Member of Institutional Lung Cancer Business Planning Committee
1996 – 1998 Member of Institutional Gastrointestinal Cancer Business Planning Committee
1996 - 2002 Member of Institutional Gastrointestinal Tumor Site Committee
1996 - 2002 Member of Institutional Central Nervous System Tumor Site Committee
1996 - 2002 Coordinator of Institutional Head & Neck Tumor Site Committee
1997 - 2000 Member of Institutional Oncology Advisory Committee
1997 - 1999 Member of Kentucky Medical Services Foundation Faculty Advisory Committee
1997 Participant in University of Kentucky Executive Development Program for Physicians
1997 - 2002 Alternate Member/Representative from Department of Radiation Medicine for Institutional Council of Chairs
1998 - 2002 Member of Markey Cancer Center Protocol Review and Monitoring System Committee
1998 - 2002 Institutional Principal Investigator for Radiation Therapy Oncology Group
1998 - 1999 Member of Institutional Associate Chiefs of Clinical Affairs Committee
1998 - 2002 Member of Institutional Tumor Registry Audit Group
1998 – 2000 Medical Director of Clinical Research Office, Markey Cancer Center, University of Kentucky
1998 - 2000 Member of Institutional Ocular & Orbital Tumors Regional Center Business Planning Committee
1998 - 1999 Member of Institutional Cancer Center Clinical Coordinating Committee
1998 - 2002 Member of Institutional Advisory Committee for Clinical Research and Investigator Services
1998 - 1999 Member of Institutional Educational Review Committee for Department of Diagnostic Radiology
1999 - 2002 Member of St. Agnes House ( Community Patient Housing Facility ) Board of Management
1999 - 2002 Member of St. Agnes House ( Community Patient Housing Facility ) Board of Management Fundraising Committee
1999 - 2002 Member of Departmental Billing Procedures Review Committee
1999 - 2002 Institutional Alternate Member/Representative for the Association of Community Cancer Centers
1999 - 2000 Member of Institutional Educational Review Committee for Department of Radiation Medicine
1999 - 2000 Director, University of Kentucky Gastrointestinal Oncology Program
1999 - 2000 Member of Institutional Clinical Research Activities Working Group
2000 - 2002 Departmental Representative for University Physicians Governing Board
2000 - 2002 Vice-President of St. Agnes House ( Community Patient Housing Facility ) Board of Management
2000 - 2002 Chairman Departmental Clinical Research Committee
2000 - 2002 Institutional Member VA Oncology Research Network
2000 - 2002 Departmental Manager of Nursing
2000 - 2002 Departmental Manager of Research Associates
2000 - 2002 Member of St. Agnes House (Community Patient Housing Facility) Board Long Range Planning Committee
2001 - 2002 Member of University Physicians Strategic Task Force
2001 - 2002 Member of Institutional Radioactive Drug Research Committee
2001 Member of Insitutional Educational Review Committee for Department of Obstetrics and Gynecology
2001 - 2002 Member of Institutional Head and Neck Cancer Clinical Care and Research Team
2001 - 2002 Director of Institutional Gastrointestinal Cancer Clinical Care and Research Team
2001 - 2002 Member of Institutional Central Nervous System Cancer Clinical Care and Research Team
2001 - 2002 Member of Instutional Strategic Task Force – Focused on Improvement in Payer Mix
2001 - 2002 Chairman of Departmental Clinical Operations Committee
2001 - 2002 Chairman of Departmental Quality Assurance Committee
2002 Member of Institutional Task Force Reviewing Faculty Salaries
2002 Member of Institutional Clincal Affairs Committee, Markey Cancer Center
2002 Coordinator of Departmental E.N.T. Resident Rotations
2002 Member of Markey Cancer Center Clinical Practices Task Force
2002 President of St. Agnes House ( Community Patient Housing Facility ) Board of Management
2002 Member of Institutional Neurosciences Business Planning Committee
2004 - 2009 Member of Institutional Clinical Affairs Advisory Committee
2004 - 2012 Member of Graduate Medical Education Committee
2004 Baltimore Area Council, Boy Scouts of America, Health Services Leadership Awards Luncheon, Event Committee Member
2005 - 2011 Member of Cancer Center Clinical Research Oversight Committee
2005 Member of Institutional Educational Review Committee for Nephrology Program
2005 - 2009 Member of Technology Research Review Committee
2005 - 2008 Member of Ambulatory Care Center Project Operations Committee
2006 - 2017 Member of University Physicians Incorporated Compliance Committee
2006 - 2009 Member of Appointment, Promotion, and Tenure Committee
2006 Member of Institutional Committee Developing Orientation Manual for New Chairs and Administrators
2007 Member of Institutional Educational Review Committee for Neuroradiology Program
2008 - 2009 Member of Appointment, Promotion, and Tenure Committee - Subcommittee to Establish Guidelines for “Non-Traditional” Candidates
2008 - 2009 Interim/Acting Chairman – Appointment, Promotion, and Teunure Committee
2008 - 2009 Member of Search and Evaluation Committee for Chairs of Emergency Medicine and Medical Research Technology Program
2009 - 2011 Member of Institutional Fiscal Affairs Advisory Committee
2010 - 2012 Member of OB/GYN Chairman Search Committee
2011 - present University Physicians Inc. Faculty Fringe Benefits Committee
2011 - 2012 Consultant for Department of Diagnostic Radiology & Nuclear Medicine Search Committee
2012 Member of Dean’s Ad-Hoc Appeals Committee for the Appointment, Promotion and Tenure Committee
2012 Member of Institutional Research Affairs Advisory Committee
2013 Member of Institutional Reportable New Information Review Committee
2013 Chairman of Dean’s Ad-Hoc Appeals Committee for the Appointment, Promotion and Tenure Committee
2013 Member of Dean’s Ad-Hoc Committee for Review of Presentation on “Vision 2020 and Strategic Disruptive Innovations for Success: Thriving in Challenging Times”
2013 Chairman of Dean’s Resource Advisory Group for Clinical Care
2013 Chairman of Dean’s Ad-hoc Subcommittee of Appointment, Promotion and Tenure – To Establish Guidelines for “Team Science” Efforts
2014 Dean’s 2014 State of the School of Medicine Planning Committee
2014 – 2016 Member of University of Maryland Medical System Clinical Performance Council
2016 – 2017 Member of University of Maryland Faculty Practices Inc. Finance Sub-Committee to address evolving deficit
2018 – present Member of University of Maryland Medical Center Capital Planning Steering Committee
2018 – present Member of University of Maryland Medical Center and School of Medicine “Steering High Reliability” / “Just Culture” Committee
2018 – present Member of University of Maryland Medical Center and School of Medicine Performance Improvement Steering Committee “PISC”
2018 – 2019 Member of School of Medicine Surgery Chairman Search Committee
2019 Member University of Maryland Faculty Practices Inc. Clinical Practice Financial Improvement Committee
2019 Chairman of School of Medicine Otorhinolaryngology Chair Search Committee
2019 Member of School of Medicine APT Committee for Remodeling the Pathway for Promotion
2019 Member of University of Maryland, Baltimore (UMB) committee on Review of Process
to Address Allegations of Research Misconduct
2019 Member of University of Maryland Medical Center CANDOR (Communication and Optimal Resolution) Project team
2019 Member of the University of Maryland Faculty Practices Inc. Clinical Affairs Advisory Committee
2020 Chairman of School of Medicine Neurosurgery Chair Search Committee
2020 Member of School of Medicine Dean's Behavior Advisory Committee (DBAC)
2020 Member of the University of Maryland Medical System ICS Policy Sub-Committee
2021 Member of the Search Committee for the Selection of the Chief Clinical Officer (CCO), University of Maryland Medical System (UMMS)
2021 Memebr of the High Reliability Organization (HRO) Steering Committee, University of Maryland Medical Center (UMMC)
NATIONAL
1994 National Cancer Institute Ad Hoc Reviewer for grants and contracts
1998 - 2002 Member of Radiation Therapy Oncology Group Full Member Principal Investigator Committee
1998 - 2002 Member of Radiation Therapy Oncology Group Head and Neck Cancer Steering Committee
1998 - 1999 Member of National Cancer Institute Gastrointestinal Cancer Strategy Committee
1998 - present Member of Radiation Therapy Oncology Group NRG Gastrointestinal Cancer Colorectal / Noncolorectal Steering Committee/ Committee
1999 - present Member of Radiation Therapy Oncology Group NRG Central Nervous System Cancer Steering Committee/ Committee
2001 - 2005 Member of Radiation Therapy Oncology Group Central Nervous System Cancer Steering Committee – Brain Metastases Working Group/Subcommittee
2001 - 2002 Member of Patterns of Care Study Committee on CNS – Role of Radiosurgery in Brain Metastases
2002 - 2004 Secretary/Treasurer for The Simon Kramer Society
2003 - 2010 Member of Genvec Data Safety Monitoring Board
2003 Member of RTOG Review Committee for proposes NCI Common Toxicity Criteria Greenebaum Cancer Center, Baltimore, MD, March, 2005. Version 3
2004 Member of External Advisory Board for Wake Forest/Ed Shaw (PI) PO-1 Application – “The RAS and Radiation Induced Brain Injury”
2005 Member of ASTRO Committee Responding to Neurosurgery Request to NRC for Gamma Knife Exemption
2006 - 2008 President for The Simon Kramer Society
2006 - 2010 Member of ACR Radiation Oncology Rectal/Anal Expert Panel
2006 - 2012 Member of Radiation Therapy Oncology Group New Investigators Committee
2006 - 2007 Member of U.S. Intergroup Hepatobiliary Cancer Clinical Trials Task Force
2007 - 2017 Member of U.S. Intergroup Pancreatic Cancer Clinical Trials Task Force
2007 Co-Chaired Radiation Therapy Oncology Group Gastrointestinal Cancer Steering Committe
2007 - 2010 Member of ASCO GI Cancer Symposium Steering Committee
2010 - 2011 Member of NCI Initial Review Group Subcommittee H – Clinical Groups
2011 - present American College of Radiation Oncology Gastrointestinal Cancer Medical Accreditation Review Team Leader
2015 – 2016 Member of Review Committee for ACR Practice Parameters for the Performance of Stereotactic Radiosurgery
2015 – 2017 Member of the Children’s Cancer Foundation (CCF) Medical Advisory Board
2016 – present Member of American College of Radiation Oncology (ACRO) Mentorship Program
2017 – present Member of Alliance for Proton Therapy Access (The Alliance) Scientific Advisory Committee
2018 – present Peer Reviewer of The American Society for Radiation Oncology (ASTRO) guideline on radiation therapy for pancreatic cancer
2020 – 2021 Member of External Advisory Committee for Mountain West Clinical and Translational Research Infrastructure Network (MW CTR-IN) – UNLV
2020 – present Member of NCI/RSS Grid/Lattice, Flash and Microbeam Radiotherapy Clinical Working Group, IExpert Panel to develop the final consensus recommendations for SFRT clinical trials in H&N cancer
2021 – present Member of American Cancer Society, Inc., Northeast Region Advisory Committee
2021 – present Member of the BigTen Cancer Research Consortium’s Sarcoma Clinical Trial Working Group
INTERNATIONAL
2001 Chairman CNS Committee – Late Effects Normal Tissues IV NCI sponsored Workshop
2004 Co-Chairman of 2nd Annual 3D Line User Meeting. 3D Line Medical Systems. Atlanta, GA, October, 2004
2005 Co-Chairman and Panel member – Pancreatic Cancer Session – International Society of Gastrointestinal Oncology – The 2005 Gastrointestinal Oncology Conference, Arlington, VA, July, 2005
2006 Co-Chairman and Panel member – Pancreatic Cancer Session – International Society of Gastrointestinal Oncology – The 2006 Gastrointestinal Oncology Conference, Arlington, VA, September, 2006
2007 Protocol Reviewer (Proposed Phase III Locally Advanced Pancreas Trial) for European Study Group for Pancreatic Cancer, (ESPAC) Trials Advisory Committee
2009 Protocol Reviewer (Proposed Phase III Adjuvant Pancreas Trial) for the German Ministry of Educational Research Medical Center Tumor Board – Bi-Monthly, 1997 – 2002
2017 - present Member of Global Advisory Board for Proton Therapy Congress
2019 Abstract Reviewer for the Particle Therapy Co Operative Group North America (PTCOG-NA) - Sixth Annual Conference. Miami, FL, October 14-16, 2019
2020 Invited Participant, “Workshop on BEYOND QUANTEC: Next-generation Modeling in Radiation Oncology”, Baltimore, MD, February 2020
2021 Abstract reviewer for the Particle Therapy Co Operative Group North America (PTCOG-NA) - Seventh Annual Conference. Seattle, WA, September 18 – 21, 2021
................
................
In order to avoid copyright disputes, this page is only a partial summary.
To fulfill the demand for quickly locating and searching documents.
It is intelligent file search solution for home and business.
Related searches
- curriculum vitae template word document
- curriculum vitae finance manager sample
- curriculum vitae format in word
- curriculum vitae sample doc
- curriculum vitae sample pdf
- curriculum vitae samples for teachers
- curriculum vitae template free download
- curriculum vitae template word download
- nursing curriculum vitae template pdf
- best curriculum vitae format
- curriculum vitae en francais modele
- curriculum vitae examples word